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SUMMARY
We envision the next generation supply chain to be an efficient, resilient, and cyberse-
cure system for the movement of goods, data, and money. An emerging design of the next
generation supply chain is reconfigurable supply chain. A reconfigurable supply chain is
a supply chain that permits material transshipment and adding, subtracting and relocating
manufacturing/service modules. Relocatable manufacturing/service module is a trending
concept in advanced manufacturing and service engineering.
In this Ph.D. thesis, we investigate a class of problems called resilient capacity plan-
ning in reconfigurable supply chains for build-to-order manufacturing systems and service-
upon-request service systems. This emerging class of problems applies to a wide spectrum
of novel application domains, such as personalized medicine, 3D-printing manufacturing,
relocatable storage network, epidemic/pandemic control and etc. The objective of this
thesis is to study capacity planning problems in reconfigurable supply chains with coordi-
nating controls on consumable and reusable resources when customer demand is stochastic
and suppliers are unreliable. We investigate several key fundamental research projects for
both centralized and decentralized reconfigurable supply chains to provide resilient capac-
ity planning decision supports. We introduce the approaches to model and quantify supplier
disruption risks in both centralized and decentralized networks and reveal the potential of




The next generation supply chain is a trending topic in both academic and industrial world.
A next-generation supply chain will be an efficient, resilient, and cybersecure system for
the movement of goods, data, and money. Moreover, The next generation supply chain
will extract value from (monetize) the significant increases in the volume, velocity, and
variety of real-time data and computational capabilities for real-time supply chain control
and competitive advantage. In this Ph.D. thesis, we aim to investigate a class of problems
in the next generation supply chain, motivated by a variety of emerging application field,
which is named as Resilient Capacity Planning.
1.1 Capacity Planning (CP) Problem
Capacity Planning (CP) [1, 2, 3] is a process of determining fulfillment capacity needed in
a manufacturing/service system to meet demand of goods or services. Fulfillment capacity
is the maximum amount of jobs that the system is capable to start given a system design of
different kinds of resources. Two major categories of these resources often considered are
reusable and consumable.
• A reusable resource is a resource that can be used by only one manufacturing/service
process at a time and is not depleted by the completion of the process. The quan-
tity of reusable resources are often limited. Examples of reusable resources include
bioreactors in personalized medicine manufacturing, 3D printers, and mobile inten-
sive care units and ventilators in epidemic/pandemic control.
• A consumable resource is a resource that is consumed (used up) by the completion
of a manufacturing/service process. The quantity of consumable resources is often
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named as ”stock” which can be produced or replenished to supply future processes.
Example of consumable resources include reagent in personalized medicine manu-
facturing, filament in 3D-printing manufacturing, and disposable medical supplies in
epidemic/pandemic control.
A demand of good or service can be fulfilled only if both reusable and consumable
resources are available. A combination of available reusable and consumable resources
constitutes one unit of fulfillment capacity. A CP problem coordinates management of
both reusable and consumable resources to ensure high fulfillment speed while minimizing
the operational costs. A CP problem distinguishes from classic inventory control problem
([4] and others) where demand are directly fulfilled by on-hand stocks, as it considers joint
effects of the reusables on the fulfillment capacity. A CP problem distinguishes from classic
lot sizing problem ([4] and others) where goods can be build-to-stock to fulfill future de-
mands, as it considers build-to-order and service-upon-request system where a fulfillment
process is triggered by product order or service request.
A CP problem should consider a planning of resources over a time horizon to cope with
demand variations, supplier uncertainties, economic climate changes and so on. Proper
solution of a CP problem aim to ensure, with high likelihood, that fulfillment capacities are
sufficient to permit a prompt manufacturing/service upon the arrival of a demand/request
while maintain a low total cost of operating the facility network and its supply chain. There
are two sub-classes of CP problems depending on the total number of the reusable resources
in the system:
• Adjustable: the quantity of reusable resources at a manufacturing/service location
can be adjusted at every decision epoch, for instance by leasing from a provider or
by transshipping from other location in the network;
• Fixed: the quantity of reusable resources at a manufacturing/service location can
only be adjusted periodically, e.g. yearly or semi-yearly, and is fixed between the
2
adjustable epochs.
The decisions of the two sub-classes are different. In an adjustable quantity model, the
decision at each decision epoch includes reusable resource adjustment and consumable
resource replenishment. While in the fixed quantity model, reusable resource adjustments
are only allowed once a while, and consumable resource replenishment is determined at
each decision epoch.
1.2 Relocatable Manufacturing/Service Module (REMO)
A standard technology that enable reconfigurability of a supply chain is the development
of RElocatable manufacturing/service MOdule (REMO). REMO is a processing unit used
for product manufacturing or request servicing. A REMO has the following key features
[5, 6]:
• Each fulfillment occupies a REMO throughout its manufacturing or service. When
increasing a system’s fulfillment capacity with REMOs, it requires to ”scale-out”
capacities by increasing the number of REMOs, instead of ”scale-up” capacities by
increasing the amount that each REMO could provide;
• When necessary, the REMOs can be relocated geographically in the manufactur-
ing/service network. In this research, we consider REMOs that can be swiftly re-
located between different locations, and easily set up at new locations. The cost of
relocating a REMO include the logistic cost and recalibration cost, which constrains
the relocations unless necessary.
Examples of REMOs inlcudes: bioreactors in personalized medicine manufacturing, 3D
printers, smart lockers in relocatable storage network, mobile intensive care units (ICU)
and ventilators in epidemic/pandemic control and etc.
A CP problem is complex as the system’s fulfillment capacity process at each location
is a modulated process affected by a REMO availability process. Breaking in a nutshell
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of the REMO availability process, the number of ready-to-use REMOs is coupled with a
number of REMO idle-busy processes. Challenges that REMOs bring to a CP problem are
three-fold:
(i) A system performance driver is the REMO availability process
(ii) Determine a proper CP decision would would require real time information of all
REMOs in the system. The vast amount of streaming data should be properly saved,
delivered and used efficiently and effectively
(iii) The complexity of system dynamics leads to the complexity of finding an optimal or
near-optimal solution of the CP.
1.3 Centralized and Decentralized Networks
A centralized network consists of a single fulfillment facility handling demands from mul-
tiple regions. While a decentralized network fulfill demands with multiple, geographically
distributed fulfillment facilities. Figure 1.1 demonstrates examples of centralized and de-
(a) Centralized (b) Decentralized
Figure 1.1: Demonstration of centralized and decentralized networks (Red dots represents
demands and green dots represents manufacturing facilities
centralized networks in the context of personalized regenerative medicine: (a) a centralized
network fulfill demands of all regions with a single facility; (b) a decentralized network
fulfill regional demands with multiple regional facilities.
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A centralized network, comparing to a decentralized network, has less regulatory re-
quirements, greater potential for economies of scale, greater consistency in operations, less
total capital expenditure, but longer fulfillment time [7]. However, decentralized networks
are able to fulfill demand with shorter fulfillment time, fewer transportation and storage of
finished goods and work-in-processes (WIPs), and less handling and packaging [7].
1.4 Reconfigurable Supply Chain
A reconfigurable supply chain is a supply chain that permits material transshipment and
allows for the adjustment and relocation of REMOs [8]. In our proposed studies of both
centralized or decentralized networks, REMOs can be added or subtracted from a fulfill-
ment facility, and can be relocated between facilities.
In a centralized reconfigurable network, adjusting the quantity of REMOS increases
operation flexibility with potential cost and fulfillment time reduction. In a decentralized
reconfigurable network, the facilities operate coordinately by transshipping both reusable
and consumable resources. A reconfigurable supply chain is resilient against system risks
such as demand uncertainty and supplier disruption. The proposed research in this thesis
will investigate reconfigurable supply chains and study how to blend the benefits of central-
ized networks with the benefits of decentralized networks while mitigating their disbenefits.
1.5 Supplier Disruption Risk
Application domains of CP with REMOs are mostly emerging industries, whose supplier
base will often have a small number of suppliers, e.g. a single supplier for a key consumable
resource. This fact leads to supplier disruption risks of key consumable resources [9]. For
instance, in the pharmaceutical industry in the US, the Food and Drug Administration often
regulates the number of suppliers to ensure the consistency and quality of the final products,
e.g. drugs and therapies. The proposed research in this thesis investigate how to model and
quantify supplier disruption risks in both centralized and decentralized networks.
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In the context of personalized medicine, a supply chain disruption due to the unavail-
ability of reagent has been a severe risk for biomanufacturers and has prompted consider-
able interest and concern in the industry. In recent years, this industry has witnessed saline
shortages due to Hurricane Maria, a severe flu season, and a 2-month shutdown of a major
regenerative medicine supplier due to sterility issues [7]. These disruptions, particularly
the delay due to sterility issues and its impact on our industry partners, e.g. The Center
for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine,
have motivated our interest in reagent disruption risk. During the most recent COVID-19
outbreak in the US, severe shortages of reagents are reported due to the production surge
of testing kits [10].
If a manufacturing/service system is operated lean without consideration of possible
supplier disruptions, the consumable resource shortages would significantly diminish the
fulfillment capacity of the system (regionally or globally). Mitigating the supplier disrup-
tion risks are challenging as the suppliers’ states are stochastic: a future supplier state is
unknown a priori, however it may be probabilistic inferred from the current supplier state.
1.6 Dynamic Resilience
The definition of supply chain network resilience has been defined in multiple perspec-
tives, including accurate detecting, tracking, gracefully degrading and rapidly responding
to and recovering from stochastic events in the supply chain. In this research, we consider
enhancing network resilience against stochastic demand and supply disruptions. In a recon-
figurable supply chain a dynamic form of resilience is possible. The design of a centralized
or decentralized reconfigurable supply chain can be dynamically adjusted according to real-
time system states. A dynamic resilient network reduces total resilience capital expenses
and allows facilities to run lean when possible and resilient when necessary.
We remark that lean/low-cost supply chains may be unable to respond effectively to
unexpected changes in demand or supply. However, such supply chains perform poorly
6
during a disruption, recover slowly after a disruption, and display a variety of previously
hidden operational risks. Dynamic resilience is an emerging and incompletely understood
feature of reconfigurable supply chains.
1.7 Domain Examples
1.7.1 Autologous cell therapy
We introduce an application domain that motivated our research on resilient capacity plan-
ning in reconfigurable supply chains. Autologous cell therapy is an emerging therapeutic
method where a patient’s own cells are used as medical treatment [11, 12]. One of the
biggest breakthroughs in cancer treatment in decades is chimeric antigen receptor T cell
(CAR-T) therapy, which has demonstrated complete response rates of 69% - 90% in pe-
diatric patients with relapsed or refractory acute lymphoblastic leukemia [13]. The Food
& Drug Administration has approved three CAR-T products to treat certain blood can-
cers: Kymriah, made by Novartis, Yescarta, made by Kite Pharma, and Tecartus, made by
UPMC Hillman Cancer Center. Building on these and other successes, large pharmaceuti-
cal companies (e.g. Pfizer, Roche) are investing heavily in gene therapy. The material and
equipment planning problem can be modeled as a CP problem.
The production of autologous cell therapy is a build-to-order process. The simplified
flow of materials and demand fulfillment in a centralized manufacturing network for an
autologous cell therapy is presented in Figure 1.2, with solid lines indicating transportation
of physical entities and dashed line indicating information flow. The manufacturing facility
Figure 1.2: Centralized autologous cell therapy manufacturing network
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acquires a specimen of patient cells from a clinic of a specific tissue, following guidelines
provided by the manufacturer. Upon the arrival of the cell specimen, an acceptance check is
conducted to ensure that this specimen is able to yield a quality final product. Each patient’s
therapy is produced independently following a carefully designed process flow shown in
1.3. Target cells are first isolated from the specimen. Then these cells are expanded and
Figure 1.3: Manufacturing process flow for autologous cell therapy [7]
harvested in a bioreactor (a device or apparatus in which living organisms synthesize useful
substances; see Figure 1.4 for an example that is small enough to be easily transportable),
consuming units of reagents (a chemical ingredient, i.e., a compound or mixture, typically
of inorganic or small organic molecules, introduced to cause the desired transformation of
an organic substance) supplied from FDA approved suppliers. We remark that a bioreactor
in autologous cell therapy production is used to manufacture a therapy for a specific, in-
dividual patient, and is portable, hence it can be considered as a REMO. Quality tests are
conducted during the cell culturing processes. The cell batch is then washed, purified, and
formulated into the customized final therapy product. A final quality test is conducted to
ensure viability of the therapy, and the cell therapy is finally cryopreserved and delivered to
the patient’s clinic for infusion. The system is unique in the structure of a closed loop where
Figure 1.4: WAVE bioreactor system 200
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the patient is both consumer and supplier of his/her autologous cell therapy. Operations in
such a system is challenging and critical not only because of a lack of empirical knowledge
of producing the unique therapy, but also because of the involvement of regulators and strict
regulatory requirements.
There are over 900 companies developing cell therapies worldwide, with a total of 1028
clinical trials as of the end of 2018 [7]. There is considerable interest in transforming clini-
cal trial empirical knowledge to large scale commercial production. Foundational research
projects proposed in this proposal are motivated by both evolving trends in the autologous
cell therapy industry and the need to transition cell therapy manufacturing to the com-
mercial arena. The recent commercial approvals of some autologous cell therapies, e.g.
Novartis’ novel CAR-T cell therapy Kymriah and Kite Pharma’s Yescarta in both the U.S.
and in Europe, is raising real world manufacturing and supply chain issues, particularly due
to the high cost of these therapies.
Currently, cost is a major barrier to the broad accessibility of these immunotherapies
[14]. Kymriah has a list price of $373,000 or $475,000, depending on the type of cancer,
and Yescarta has a list price of $373,000. These list prices are only a portion of the total
cost of treatment, which include the CAR-T infusion, doctors’ services and hospital stays,
but do not include time away from work and living expenses away from home if the patient
has to travel to the infusion site, can easily exceed $750,000. As a result, there is consider-
able interest in cost reduction with the help of good capacity planning to minimize capital
investments and inventory costs. We note that cost reduction is a fundamental, but not ex-
clusive, goal of the proposed research. Cost reduction must take into consideration various
types of risk. Autologous cell therapy is an emerging industry with an emerging supplier
base. Supply chain disruption due to the unavailability of a reagent has been a severe risk
for biomanufacturers and has prompted considerable interest and concern in the industry.
The networks of interests are a centralized manufacturing network, a decentralized
manufacturing network with independently operated facilities and a decentralized man-
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ufacturing network allowing specimen/reagent transshipment and bioreactor relocation.
Solving CP problem in these network will (1) provide direct insights to plant managers
on determination of bioreactor adjustment and reagent replenishment decisions, (2) pro-
vide the pharmaceutical company about cost and resilience of each network designs, (3)
refine the manufacturing network design with consideration of major supplier disruption
risks, (4) cope with regulatory policies with respect to patient accessibility.
1.7.2 Epidemic/pandemic control
The recent rapid spread of COVID-19 virus has huge impacts on the healthcare network
nationally and globally. The healthcare service network as well as its supply chain of
medical countermeasures is ripped due to critical medical supplies shortages. The shortages
of personal protection equipment (PPE) have positioned doctors and nurses on the front line
of this invisible war in great danger; and the shortages of ventilators, treatment rooms and
ICUs have led to an extensive number of patient moralities in Wuhan and New York. The
medical supplies and equipment planning problem can be modeled as a CP problem.
The treatment of a hospitalized patient can be modeled as a request-to-service process.
When a patient develops acute respiratory distress syndrome, the patient requires occupa-
tion of life supporting equipment, e.g. a ventilator and other ICU equipment, for an exten-
sive period of time; and the treatment of the patient consumes a bundle of drugs and medical
supplies. The treatment of a critical condition patient can only be fulfilled when a life sup-
porting equipment, drugs and other medical supplies are available. We highlight that a life
supporting equipment can serve one patient at a time, and is sterilized before its use on an-
other patient, and thus is considered reusable. Most of these equipment are portable. Other
relocatable reusable resources in this domain include mobile ICUs, makeshift hospitals and
portacabins. Hence these resources can be considered as REMOs, and epidemic/pandemic
control network and its supply chain can be considered reconfigurable.
Supplier disruptions lead to critical shortages of PPE during the coronavirus season.
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The world’s major PPE suppliers are located overseas, e.g. China and Vietnam. With the
catastrophic outbreak of COVID-19 in China, the supply channels of PPE in the US are
disrupted, causing life threatening PPE shortages in the decease control network. On the
other hand, regional shortages of ventilators and hospital beds contribute to bottlenecks of
regional (state-level) fulfillment capacities. The national and state-level stockpiles MCMs
(e.g. PPE, ventilators and antibiotics) are insufficient compared to the boosting of con-
firmed cases of COVID-19. A resilient epidemic/pandemic control network with the ability
to mitigate risks of supplier disruptions and regional demand surge is required.
The epidemic/pandemic control network can be considered as a decentralized service
network. The state-level healthcare facilities can be simplified as a service node provid-
ing treatment for regional patients. On the federal level, national stockpiles of MCMs as
well as other resources (e.g. military makeshift hospitals, mobile ICUs, mobile hospitals
and etc.) can be risk-pooled to provide relocatable capacity across the national network.
The networks of interests are a decentralized service network with independently oper-
ated regions and a decentralized service network allowing transshipment of consumable
resources and relocation of reusable resources. Solving CP problem in these networks
will (1) guide the capacity planning on both federal and state level to increase readiness
for disease outbreaks and other natural disasters, (2) reveal the importance of federal level
MCMs stockpile for cost-efficiency, (3) refine the service network design with considera-
tion of major supplier disruption risks, (4) propose a inter-state coordination in combating
the epidemic/pandemic.
1.8 Objectives and Organization
Our research objectives include but are not limited to
(1) investigation on how to conduct capacity planning in centralized and decentralized
networks with simultaneous control of both equipment quantity and inventory level
of critical material;
11
(2) Modeling and quantification of supplier disruption risks in both centralized and de-
centralized networks;
(3) Revealing the costs and benefits of dynamic resilience in both centralized and decen-
tralized networks.
The research findings and knowledge can be extended to a wide spectrum of application
domains with managerial tasks in capacity planning of both reusable and consumable re-
sources, in order to 1) reduce total manufacturing/service and logistic costs, 2) ensure high
service level, and 3) ensure system resilience against supplier disruption risks. All pro-
posed models and algorithms can be easily translated to applicable domains not limited to
personalized medicine, 3D-printing manufacturing, relocatable storage network, and epi-
demic/pandemic control.
This thesis is organized as follows. In Chapter 2, we investigate approaches for de-
termining the number of reusable resources and a replenishment policy for consumable
resources in a centralized network, e.g. an autologous build-to-order cell therapy man-
ufacturing system. We consider two capacity planning models, one where the number
of bioreactors is adjustable at each decision epoch and one where this number can only be
adjusted periodically. For each model, we examine two variants, one where there are penal-
ties for an insufficient number of bioreactors and units of reagents and one where there are
chance constraints on an insufficient number of bioreactors and units of reagents. In a case
study, we determine an optimal or near-optimal number of bioreactors and a reagent replen-
ishment policy based in part on data collected from a CAR-T cell therapy manufacturing
facility at the University of Pennsylvania.
In Chapter 3, We investigate approaches to determine the number of reusable resources
and a replenishment policy for consumable resources in a centralized network, e.g. an au-
tologous build-to-order cell therapy manufacturing system, when confronted with supplier
disruption risks. We model a supplier disruption process as an exogenous Markov process.
Incidents that cause reagent shortages include natural disasters, human errors and disease
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outbreaks. We consider two capacity planning models, one where the number of bioreac-
tors is adjustable at each decision epoch and one where this number can only be adjusted
periodically. Both models are formulated as Markov decision processes (MDP). We pro-
pose algorithms to solve the proposed models. In the case studies, given different supplier
disruption scenarios, we determine bioreactors adjustment quantities and reagent replen-
ishment policies based in part on data collected from a CAR-T cell therapy manufacturing
facility at the University of Pennsylvania.
In Chapter 4, we investigate a capacity planning problem in a decentralized network
when confronted with supplier disruption risks. We consider two kinds of decentralized
networks. The first network has isolated regional facilities (Iso-Net), while the second
network has coordinated regional facilities (Co-Net). In an Iso-Net, each facility fulfills
its regional demand with its own capacity; while in a Co-Net, all facilities coordinate by
sharing demand and transshipping resources (bioreactor and reagent). The second supply
chain is reconfigurable as production capacities in different facilities are dynamically ad-
justable. We show that a coordinating and reconfigurable decentralized network exhibits
greater resilience with lower costs in the face of supplier disruption risks. In the case
studies, we construct a hypothetical decentralized network based in part on data collected
from a CAR-T cell therapy manufacturing facility at the University of Pennsylvania. We
compare decentralized models and different heuristic polices based on the constructed de-
centralized network. Testing results suggest that instead of increasing resource redundancy
in all facilities, it is beneficial to only restore limited level of redundancy and adaptively
reconfigure the network.




RESILIENT CAPACITY PLANNING IN A CENTRALIZED NETWORK
In this chapter, we introduce a Capacity Planning (CP) problem in a centralized network.
We demonstrate problem settings and notations in the context of autologous cell therapy.
Translating all models, algorithms and results to other domains is straightforward.
We investigate approaches for determining the number of reusable resources and a re-
plenishment policy for consumable resources for an autologous build-to-order cell therapy
manufacturing system. We assume therapy manufacturing for a patient can only begin if
there is a patient specimen, an idle bioreactor (assumed to be reusable), and a unit of reagent
(a consumable) at the manufacturing facility. Patients who qualify for such cell therapies
have serious and even life-threatening diseases, and delays in therapy manufacturing can
increase patient mortality rate. Hence, it is important for an idle bioreactor and a unit of
reagent to be available when a patient’s specimen arrives at the facility. However, cell
therapy manufacturing is very expensive. We consider two capacity planning models, one
where the number of bioreactors is adjustable at each decision epoch and one where this
number can only be adjusted periodically. For each model we examine two variants, one
where there are penalties for an insufficient number of bioreactors and units of reagents and
one where there are chance constraints on an insufficient number of bioreactors and units
of reagents. In a case study, we determine an optimal or near-optimal number of bioreac-
tors and a reagent replenishment policy based in part on data collected from a CAR-T cell
therapy manufacturing facility at the University of Pennsylvania.
2.1 Introduction
Autologous cell therapy is an emerging therapeutic method that has proven to be dramati-
cally effective for treating serious and even life-threatening diseases, such as various can-
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cers, cardiovascular disease, liver disease, diabetes, neuro-degenerative disorders, bone re-
pair, and spinal cord injuries. Autologous cell therapy is a form of ”personalized” medicine,
manufactured for a specific patient that harnesses the patient’s own immune system in the
production of the therapy. As the emerging cell therapy manufacturing industry moves
from clinical trials to commercialization, the need for capacity planning becomes of crit-
ical importance. The intent of this thesis is to address a key capacity planning challenge
for the industry – determining an optimal level of manufacturing capacity and an optimal
replenishment policy for an important consumable required during the cell therapy manu-
facturing process.
The autologous cell therapy manufacturing supply chain begins by drawing a speci-
men from the patient at the patient’s point-of-care (POC; e.g., clinic, hospital) and ends
with infusing the resulting therapy in the same patient at the patient’s POC [15]. Once the
specimen is drawn from the patient, it is then transported to the cell therapy manufacturing
facility, where initially an acceptance check is conducted to ensure that this specimen is
able to yield a quality final product; e.g., the specimen must contain a sufficient amount
of primitive multipotent stem or progenitor cells from the patient’s bone marrow, adipose
tissue, peripheral blood and other specific tissues to support therapy production. If the ac-
ceptance check is successful, target cells are first isolated from the specimen. Then these
cells are expanded and harvested in a bioreactor (a device or apparatus, which we assume
is reusable, in which living organisms synthesize useful substances), consuming units of
reagents (a chemical ingredient, i.e., a compound or mixture, typically of inorganic or
small organic molecules, which we consider a consumable, introduced to cause the desired
transformation of an organic substance) supplied from FDA approved suppliers. Quality
tests are conducted during the cell culturing processes. The cell batch is then washed,
purified, and formulated into the customized final therapy product. A final quality test is
conducted to ensure viability of the therapy. The cell therapy is finally cryopreserved and
delivered to the patient’s POC for infusion. Each patient’s therapy is produced, separate
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from the production of other patients’ therapies, and is not interchangeable. A patient’s
therapy manufacturing can only begin after the patient’s specimen is received at the man-
ufacturing facility and once there is an available idle bioreactor and an available unit of
reagent.
This process is build-to-order and complex due to the stochastic and dynamic natures
of the biologic product and patient status. Operations in such a system are challenging and
critical not only because of a lack of empirical knowledge of producing the unique ther-
apy, but also because of the involvement of regulators and strict regulatory requirements.
Additional detail regarding the manufacturing process and the rapidly emerging cell man-
ufacturing industry can be found in [7] and [16].
The objective of this thesis is to develop and analyze a tractable (and hence necessarily
simplified) stochastic optimization model of the cell therapy manufacturing process that can
provide insights directly to the manager of the manufacturing facility for answering two key
capacity planning questions, given cost information and information about the specimen
arrival process: What is the number of bioreactors needed for therapy production? What
is a good reagent replenishment policy? Further, we will show that the insights derived
from the analytical model can be useful to reduce simulation computation time and the
number of simulations for a simulation of the cell therapy manufacturing process. The
value of such a simulation is that it can support a far more detailed and hence more realistic
description of this process than the stochastic optimization model can and can produce
detailed information valuable at an operational level.
2.1.1 Literature review
Autologous cell therapy manufacturing is an example of build-to-order (BTO), a manu-
facturing approach where product manufacturing may only begin after the order for the
product is received. BTO is a particularly appropriate manufacturing approach for highly
customized and/or low volume products such as autologous cell therapies. BTO has proved
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to be a successful manufacturing approach for many companies in a variety of industries,
e.g., consumer electronics, automotive ([1, 2, 3]).
Capacity planning (CP) is the process of determining the production capacity needed
to meet product demand. Production capacity is variable for the domain considered in this
thesis; at decision epoch t, production capacity equals the minimum of (i) the number of
idle bioreactors at t and (ii) the number of units of reagents in inventory at t. Although
workforce development is a major challenge for this industry, workforce capacity is not
considered in this thesis for model simplicity and enhanced model tractability. A capacity
planning that considers multiple product lines and facilities and assumes production capac-
ity is pre-determined over the planning horizon has been studied by [17], [18], [19], and
[20]. [17] modelled demand as a finite set of demand scenarios, [18] use point-estimate
forecasts of demand, and [19] considered cumulative distribution functions to describe de-
mand. [19] also assumed that the production capacity of a facility is dependent on work-
force capacity, modelled the capacity planning problem as a multi-stage mixed integer pro-
gram (MIP), and developed a two-stage heuristic for determining a near-optimal solution
to the MIP. [21] extended the model presented in [19] to a multi-stage dynamic program
(DP). [20] considered a multi-stage CP problem with service constraints to determine ma-
terial planning in a multi-echelon production supply chain.
Capacity planning for a single production site has been studied by [22], [23], and [24].
[22] proposed a deterministic MIP to determine workforce plans so that build-to-order de-
mands can be satisfied with a minimum number of workers. [23] developed a DP approach
to manage inventory and production capacity adjustments based on sales forecasts, work-
force constraints, and manufacturing lead time and proposed a rule-based heuristic to find
a feasible solution to the computationally challenging DP. [24] minimized the total cost of
capacity changes and operations over a finite planning horizon for a CP problem. We re-
mark that none of these studies considered material management. However, each assumed
additional staffing could reduce manufacturing lead time, which is currently not a realistic
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assumption for autologous cell manufacturing.
As autologous cell therapy transitions from clinical trials to commercialization, ca-
pacity planning and material management have become of greater interest to industry.
Challenges in production capacity planning and material management for autologous cell
therapy manufacturing are discussed in [7], [16] and [25]. [7] proposed an agent-based
simulation framework to construct a simulation ‘digital twin’ model of an autologous cell
therapy manufacturing facility network and used the simulation model to examine several
issues of importance to the emerging industry, e.g., supply chain cost reduction, supplier
disruption impacts on network productivity, the impact on patient benefit of different queu-
ing disciplines for patient specimens arriving at a manufacturing facility, the impact on
network resilience and productivity on manufacturing capacity and reagent inventory pol-
icy, the number of bioreactors and units of reagent a cell manufacturing facility should
have available. [16] presented an overview of the current state of the art and challenges
in autologous cell manufacturing. They emphasized the importance of developing oper-
ational level analytical models to support supply chain capacity planning decisions using
mathematical programming approaches. [25] discussed capacity allocation at a strategic
level in an autologous cell therapy manufacturing network. None of this research examines
analytical approaches for determining an optimal or near-optimal level of manufacturing
capacity (e.g., the number of bioreactors) or an optimal or near-optimal reagent inventory
replenishment policy.
Our interest in chance-constrained dynamic programming (CCDP) is due to we be-
lieve and based on our experience that chance constraints are easier for assessing key sys-
tem parameters from healthcare providers than assessing (a different set of) key system
parameters for a standard DP model of a cell manufacturing network. The CCDP was
initially motivated by water management problems [26, 27]. Solution methods for con-
strained Markov decision processes due to [28] have been adopted to solve the CCDP if
the chance constraints can be formulated so that they share the same additive structure of
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the objective function [27, 29, 30]. Several reformulation approaches have been proposed
by [31]. [30] considered a CCDP with a joint chance-constraint that violated the additive
structure requirement using a heuristic developed by a conservative approximation of the
joint probability using an approach based on Boole’s inequality.
2.1.2 Organization
Our thesis is outlined as follows. We consider two capacity planning models, one where the
number of bioreactors is adjustable at each decision epoch (Section 2.2) and one where this
number can only be adjusted periodically (Section 2.3). For each model we examine two
variants, one where there are penalties for an insufficient number of bioreactors and units of
reagents (Section 2.2.1 and Section 2.3.1) and one where there are chance constraints on an
insufficient number of bioreactors and units of reagents (Section 2.2.2 and Section 2.3.2).
For the case where the number of idle bioreactors can be adjusted at each epoch and for both
variants of this case, we will show that this number and the reagent replenishment policy
are both myopic and base stock. For the case where the number of bioreactors can only be
adjusted periodically, we will present near-optimal heuristics for determining the number
of bioreactors and the reagent replenishment policy. In a case study in Section 2.4, we
determine an optimal or near-optimal number of bioreactors and a reagent replenishment
policy based in part on data collected from a CAR-T cell therapy manufacturing facility at
the University of Pennsylvania.
2.2 Adjustable Bioreactor Quantity (ABQ) Model
We now present an infinite horizon total discounted cost Markov Decision Process (MDP)
model of the reagent replenishment and bioreactor quantity selection processes, assuming
that at each decision epoch we can (i) replenish the reagent inventory instantaneously and
(ii) adjust the number of idle bioreactors held at the facility instantaneously. Instantaneous
replenishment of reagents is an unrealistic assumption; in reality, there are time lags (often
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stochastic) between order placement and order receipt. The assumption that the number of
idle bioreactors (and hence the total number of bioreactors at the facility) can be adjusted
at each decision epoch instantaneously may be realistic if the facility manufactures several
cell therapy lines, the bioreactors needed for each cell therapy line are interchangeable, and
there is a substantial number of ’buffer’ bioreactors in the facility. However, for a facility
that manufactures only a single therapy, the total number of bioreactors at the facility would
be more realistically adjusted only periodically. Nevertheless, the assumptions (i) and (ii)
above ensure tractability and we will find the solution to this problem useful in addressing
both of the questions: What is the number of bioreactors needed for therapy production?
What is a good reagent replenishment policy? More specifically, we will find the solution
to the adjustable bioreactor case useful in limiting the simulation search for an optimal
number of bioreactors can only be adjusted periodically.
We now present the adjustable bioreactor quantity (ABQ) model. Assume at decision
epoch t that
• st ≥ 0 is the number of specimens in the arrival queue, waiting for therapy manufac-
turing to begin;
• bτt ≥ 0 is the number of bioreactors that are τ epochs from completing the manufac-
turing process. Let bt = (b0t , . . . , b
T−1
t ), where T epochs are required to complete
the manufacturing process and b0t is the number of idle bioreactors;
• rt ≥ 0 is the number of units of the reagent in inventory. In reality, multiple reagents
(e.g., media, recombinant proteins, viral vectors, scaffolds, and other critical mate-
rials) are required for therapy manufacturing. We consider a unit of reagent to be a
collection of the multiple reagents needed to manufacture a single therapy.
Let xt = (st,bt, rt) be the system state at epoch t.
Further, assume
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• 0 ≤ mt ≤ min{st, b0t , rt}, a decision variable, is the number of therapies starting at
time t. Thus, a patient’s therapy production can only begin if the patient’s specimen
is in the arrival queue and there is an idle bioreactor and one unit of each type of
reagent at the manufacturing facility that can be assigned to the specimen
• dt is the number of specimens that arrive between epoch t and epoch t + 1. We
assume that the stochastic process {dt, t ≥ 0} is a sequence of independent, identi-
cally distributed random variables with known distribution, where the realization of
dt becomes available to the decision maker just before epoch t+ 1
• qt, a decision variable, is the number of idle reactors either added to the current
number of idle reactors (in which case qt is non-negative) or subtracted from the
current number of idle reactors (in which case qt is non-positive) at epoch t and is
received or removed before epoch t+ 1
• at ≥ 0, a decision variable, is the number of units of the reagent ordered at epoch t
and received before epoch t+ 1.
We assume mt, qt and at are determined based on knowledge of xt. The resulting system
dynamics are:
st+1 = st −mt + dt,
bτt+1 =

b0t −mt + b1t + qt τ = 0,
bτ+1t 1 ≤ τ ≤ T − 2,
mt τ = T − 1,
rt+1 = rt −mt + at.
from which we obtain an updated system state xt+1. Since the number of idle bioreactors
is non-negative, qt ≥ −(b0t − mt + b1t ), where b0t − mt + b1t is the maximum number of
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bioreactors that can be removed from the system.
In the remainder of this section, we introduce two modeling approaches, a classic
penalty cost approach in Section 2.2.1 and a chance constraint approach in Section 2.2.2, to
determine optimal capacity planning policies. The connection between the two approaches
is presented in Section 2.2.3.
2.2.1 Penalty cost approach
Assume the single period costs accrued between epoch t and t+ 1 are as follows:
• cRat is the reagent replenishment cost for the reagent, where cR is the cost per unit
of regent
• cBqt is the bioreactor adjustment cost or savings, where cB is the cost or savings per
bioreactor, depending on whether qt is positive or negative
• hR(rt+1 − st+1)+ is the random variable holding cost for the reagent, charged only
if there are more units of reagent than specimens at epoch t + 1, where hR is the
holding cost per unit of reagent
• hB(b0t+1 − st+1)+ is the random variable bioreactor holding cost, charged only if
there are more bioreactors than specimens at epoch t+ 1, where hB is the bioreactor
holding cost per bioreactor
• pR(st+1− rt+1)+ is the random variable penalty for having an insufficient number of
units of reagent in order to start therapy manufacturing for all specimens that have
arrived at the facility and are waiting for therapy production to begin
• pB(st+1 − b0t+1)+ is the random variable penalty for having an insufficient number
of idle bioreactors in order to start therapy manufacturing for all specimens that have
arrived at the facility and are waiting for therapy production to begin.
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We now present the optimality equation for the ABQ model with penalty cost (ABQ-
p), assuming an infinite horizon total discounted cost MDP model with discount factor
β ∈ [0, 1). Let
[Hv](xt) = min
0 ≤ mt ≤ min{st, b0t , rt}
qt ≥ −(b0t −mt + b1t ), at ≥ 0
E{C(qt, at,mt, dt|xt) + βv(xt+1)} (ABQ-p)
where
C(qt, at,mt, dt|xt) =cRat + hR(rt+1 − st+1)+ + pR(st+1 − rt+1)+
+ cBqt + hB(b
0
t+1 − st+1)+ + pB(st+1 − b0t+1)+
is the single period cost function. Results in [32] guarantee the existence of a unique fixed
point v∗ such that limn→∞ ‖vn − v∗‖ = 0, where {vn} is such that v0 = 0, vn+1 = Hvn
for all n, and ‖ · ‖ is the sup-norm. Further, a policy that achieves the minimum in Hv∗
is an optimal policy. Thus, by determining the fixed point of the operator H , the capacity
planner obtains an optimal reagent replenishment policy and an optimal idle bioreactor
adjustment policy. Our next result presents a simple, easily implemented and computed
policy that is optimal for the ABQ-p, assuming Assumption (A1) holds, which we assume
holds throughout the remainder of the thesis.






An interpretation of A1 is that the initial amount of reagent in inventory is insufficient to
support cell therapy manufacturing for the initial number of specimens in the arrival queue
added to a number that represents the number of specimens expected to arrive in the next
period plus an amount of buffer reagent inventory determined by the cost structure and the
cumulative density function (CDF) of demand. We now present an optimal policy for the
ABQ-p.
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Proposition 2.2.1. If A1 holds, the following policy is optimal for the ABQ-p












pB − (1− β)cB
pB + hB
)
− (b0t + b1t ) (2.1b)
mp(xt) = min{st, b0t , rt}. (2.1c)
A proof of Proposition 2.2.1 is presented in Appendix A. We remark it is straightfor-
ward to show that if A1 holds for epoch t and if the policy presented in Proposition 2.2.1
(2.1a) is used, then A1 will hold for epoch t+1. Further, we note that policy (2.1) is myopic
and easy to implement.
An alternative model of the penalty cost pR(st+1−rt+1)++pB(st+1−b0t+1)+ is p(st+1−
mt+1)
+. We assume that C(qt, at,mt, dt|xt) is our single period cost function throughout
the remainder of this thesis due to the existence of the easily implemented and computed
optimal policy presented in Proposition 2.2.1. However, for the moment, let
Ĉ(qt, at,mt, dt|xt) =C(qt, at,mt, dt|xt)− (pR(st+1 − rt+1)+ + pB(st+1 − b0t+1)+)
+ p(st+1 −mt+1)+
and consider the resulting optimal equation
v(xt) = min
0 ≤ mt ≤ min{st, b0t , rt}
qt ≥ −(b0t −mt + b1t ), at ≥ 0
E{Ĉ(qt, at,mt, dt|xt) + βv(xt+1)}. (2.2)
A relationship between ABQ-p and (2.2) is presented in the following result, the proof of
which is found in Appendix A.
Corollary 2.2.2. If pB + pR = p and pR−(1−β)cRpR+hR =
pB−(1−β)cB
pB+hB
, then ABQ-p and (2.2) have
a same optimal policy (qp, ap,mp).
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We remark that cR, cB, hR, and hB are cost values that are straightforward to determine,
relative to the penalty parameters pR and pB, which require assessment from an individual
or individuals involved in the decision-making process. The penalty parameters represent
penalties, in monetary units, of delaying the beginning of therapy manufacturing and hence
delaying the beginning of treatment one period for a single patient. A delay in beginning
treatment for patients with extremely serious health conditions such as those treated by
autologous cell therapies can increase the mortality risk of these patients. Based on our
experience in assessing such parameters from human subjects [33], we anticipate that it
may be difficult to directly assess the penalty parameters. Further, in this domain we have
found human decision makers easily provide chance constraints useful for indirectly as-
sessing the penalty parameters. For these reasons, we next consider an alternative chance
constraint-based problem formulation that is straightforward to solve and serves as a path
to indirectly determining the penalty parameters.
2.2.2 Chance constraint approach
Consider the following modification of the problem presented in Section 2.2.1. The ap-
proach suggests to remove the penalty terms from the single period costs and replace them
with two chance constraints
Pr[st+1 > b
0
t+1|xt] ≤ αB, ∀t;
Pr[st+1 > rt+1|xt] ≤ αR, ∀t.
where αB and αR are presumably small probabilities that must be assessed from the individ-
ual or individuals involved in the decision making process. We have found that clinicians
provide these probabilities with little effort or concerns. The probability (1 − αR) repre-
sents the probability that a patient whose specimen arrives at the facility between epochs
t and t + 1 will have a unit of reagent available at epoch t + 1 so that therapy produc-
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tion can begin at t + 1. Similarly, the probability (1 − αB) represents the probability that
a patient whose specimen arrives at the facility between epochs t and t + 1 will have a
bioreactor available at epoch t + 1 so that therapy production can begin at t + 1. Hence
the revised model becomes an infinite horizon chance constrained dynamic programming
problem with discount factor β ∈ [0, 1)
v(xt) = min
0 ≤ mt ≤ min{st, b0t , rt}
qt ≥ −(b0t −mt + b1t ), at ≥ 0
E{C̃(qt, at,mt, dt|xt) + βv(xt+1)} (ABQ-c)
s.t. Pr[st+1 > b
0
t+1|xt] ≤ αB,
P r[st+1 > rt+1|xt] ≤ αR,
where
C̃(qt, at,mt, dt|xt) =cRat + hR(rt+1 − st+1)+ + cBqt + hB(b0t+1 − st+1)+.
Let Assumption A2 be defined as follows:
Assumption (A2). r1 ≤ s1 + F−1d (1− αR).
Noting the close resemblance of A1 and A2, we now present an optimal policy for
ABQ-c.
Proposition 2.2.3. An optimal reagent replenishment policy and an optimal bioreactor
adjustment policy for ABQ-c is to select
a∗(xt) = (st + F
−1
d (1− αR)− rt)
+ (2.3a)
q∗(xt) = st + F
−1





m∗(xt) = min{st, b0t , rt}, (2.3c)
and if A2 holds, a∗(xt) = st + F−1d (1− αR)− rt.
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Recall that if A1 holds for epoch t and the policy (2.1a) in Proposition 2.2.1 is followed,
then A1 holds for epoch t + 1. Similar, it is straightforward to show that if A2 holds for
epoch t and policy (2.3a) in Proposition 2.2.3 is followed, then A2 holds for epoch t + 1.
Similar to (2.1), we remark that policy (2.3) is myopic and easy to implement.
2.2.3 Connections between ABQ-p and ABQ-c
Our next result follows by comparing policies (2.1) and (2.3).
Corollary 2.2.4. If αB = hB+(1−β)cBpB+hB and αR =
hR+(1−β)cR
pR+hR
, then ABQ-p and ABQ-c have
identical optimal bioreactor adjustment and reagent replenishment policies.
Corollary 2.2.4 suggests that probabilities αB and αR are equivalent to penalty costs
pB(αB) =




(1− αR)hR + (1− β)cR
αR
. (2.4b)
We now further present connections between ABQ-p and ABQ-c through a primal-dual
method. Since an optimal production decisionm(xt) is shown always to equal min{st, b0t , rt},
we substitute mt = min{st, b0t , rt} in ABQ-p and ABQ-c through the remainder this sec-
tion. The chance constraints in ABQ-c can be rewritten as qt ≥ ZB + st − (b0t + b1t ) and
at ≥ ZR + st − rt, where ZB = F−1d (1− αB) and ZR = F
−1
d (1− αR). Therefore, ABQ-c





βt−1E{C̃(qt, at,mt, dt|xt)} (2.5)
s.t. qt ≥ ZB + st − (b0t + b1t ), ∀t;
at ≥ ZR + st − rt, ∀t;
qt ≥ −(b0t −mt + b1t ), ∀t;
at ≥ 0, ∀t.
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We relax the first and second set of constraints with Lagrangian multipliers µB,t ≥ 0 and








βt−1E{L(qt, at,mt, dt|xt, λB,t, λR,t)} (2.6)
s.t. qt ≥ −(b0t −mt + b1t ), ∀t;
at ≥ 0, ,∀t,
where
L(qt, at,mt, dt|xt, λB,t, λR,t) =C̃(qt, at, dt|xt) + λB,t(ZB + st − (qt + b0t + b1t ))
+ λR,t(ZR + st − rt − at),






βt−1E{L(qt, at,mt, dt|xt, λB,t, λR,t)}
s.t. qt ≥ −(b0t −mt + b1t ), ∀t;
at ≥ 0, ∀t
is jointly convex in λB,t and λR,t for all t, and hence there exists an optimal dual solution
{λ∗B,t, λ∗R,t : t ≥ 0} (see [34]). By strong duality, (q∗t , a∗t ) defined in (2.3) is optimal for
v(xt) = min
qt≥−(b0t−mt+b1t ),at≥0
E{Lt(qt, at,mt, dt|xt, λ∗B,t, λ∗R,t) + βv(xt+1)}. (2.7)
Then by Corollary 2.2.4 and matching up the terms in (q∗t , a
∗




t ), there exists a
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(1− αR)hR + (1− β)cR
αR
= pR(αR) (2.8b)
which are marginal costs of constraints qt ≥ ZB + st− (b0t + b1t ) and at ≥ ZR + st− rt for
all t. We remark that λ∗B and λ
∗
R are functions of αB and αR respectively. We note that λ
∗
B
is monotonically decreasing in αB, implying that the marginal cost of violating Pr[st+1 >
b0t+1] ≤ αB is monotonically increases in αB. Similarly, since pB(αB) is monotonically
decreasing in αB, a reduction in αB implies an increase in pB(αB). Similar results hold for
the chance constraints on reagent outages and the penalty cost on an insufficient number
of units of reagent. We remark that by establishing capacity outage probability thresholds,
the chance constraint model implies underlying costs to ensure that the chance constraints
are satisfied through their marginal costs (λ∗B and λ
∗





is directly related to penalty costs (pB(αB) and pR(αR)) in the penalty cost model, the
primal-dual results explicitly show how the two models are interrelated.
2.3 Fixed Bioreactor Quantity (FBQ) Model
We now consider the case where the number of bioreactors can only be readjusted peri-
odically, i.e., every T decision epochs, rather than at each epoch (the T = 1 case). We
expect T to be significantly larger than T . For example, assume the time between decision
epochs is one week, three weeks are required to manufacture a therapy, and the number of
bioreactors can be adjusted quarterly. Then, T = 3 and T = 13. We refer to this problem
as the fixed bioreactor quantity (FBQ) model.
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2.3.1 Penalty cost approach
Let the operator H̄ be defined as
[H̄v](xt) = min
at≥0
E{C(0, at, dt|xt) + βv(xt+1)}.
Define the sequence {vτ,n} as:
vτ,n(xt) = [H̄vτ+1,n](xt), 2 ≤ τ ≤ T ,
v1,n(xt) = [Hv2,n](xt),
(FBQ-p)
vT +1,n+1 = v1,n, and assume vT +1,0 = 0. Results in [32] imply that there exists a set
{vτ , τ = 1, ..., T + 1} such that this set is the unique solution to v∗τ = H̄v∗τ+1 for τ =
2, ..., T , v∗1 = Hv∗2 , and v∗1 = v∗T +1, and limn→∞ ‖vτ,n − v∗τ‖ = 0 for τ = 1, ..., T + 1,
where ‖ · ‖ is the sup-norm. Further, a policy π∗τ that achieves the minimum in H̄vτ+1 for
τ = 2, ..., T and the minimum in Hv2 for τ = 1 is an optimal policy.
Unfortunately, the optimal policy structure in Proposition 2.2.1 (2.1b) does not extend
to the T > 1 case. This loss of structure and the resulting computational burden of deter-
mining an optimal policy for FBQ-sdr motivates interest in examining heuristic procedures.
Consider the following procedure for determining a near-optimal policy for FBQ-sdr.
Let x1 be such that r1 − s1 ≤ F−1d (
pR−(1−β)cR
pR+hR
). Fix the reagent replenishment decision as





) − rt for all t ≥ 0, which is guaranteed to be nonnegative
since rt − st ≤ F−1d (
pR−(1−β)cR
pR+hR
) for all t. Given this policy, for 2 ≤ τ ≤ T , let
v̂τ,n(xt) = E{C(0, ât, dt|xt) + βv̂τ+1,n(xt+1)},
where rt+1 = rt −mt + ât = st −mt + F−1d (
pR−(1−β)cR
pR+hR
) for all t. Then we determine the
30
bioreactor adjustment quantity by solving
v̂1,n(xt) = min
qt≥−(b0t−mt+b1t )
E{C(qt, ât, dt|xt) + βv̂2,n(xt)}.
Thus, there exists a unique set {v̂∗τ , τ = 1, ..., T + 1} such that v̂∗1 = v̂∗T +1,
v̂∗τ (xt) = E{C(0, ât, dt|xt) + βv̂∗τ+1(xt+1)},
for 1 ≤ τ ≤ T + 1, and
v̂∗1(xt) = min
qt≥−(b0t−mt+b1t )
E{C(qt, ât, dt|xt) + βv̂∗τ+1(xt+1)}.
Let the heuristic policy for adjusting the number of bioreactors achieve the above minimum.
Upper and lower bounds are
v∗(xt) ≤ v∗τ (xt) ≤ v̂∗τ (xt), 1 ≤ τ ≤ T + 1,
where we recall that v∗ is the fixed point of H and the optimal value function for ABQ-
p. We now present a preliminary numerical analysis of this heuristic, based on CAR-T
manufacturing facility specifications given in [7].
Example 1: Assume the demand distribution is Poisson with a mean of 250 patients
per year, production duration is T = 3 weeks and the planning horizon T = 52 weeks.
Based on data presented in [14], let cR = $42, 174, hR = $113.50, cB = $25, 000 and
hB = $14.40. By Corollary 2.2.4, if the total number of bioreactors is adjustable and
β = 0.9, then it is equivalent to charge pR = $50, 273.60 and pB = $86, 504.50. Let x1 =
(0,0, 0), which assumes the facility starts with an empty queue and no reagent inventory.
It follows that v∗(x1) = $2, 704, 336.72 for v∗1(x1), and v̂
∗
1(x1) = $2, 799, 168.49 (with 21
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Thus, the expected cost accrued by the heuristic is no more than 3.5% higher than the
optimal expected cost of FBQ-sdr.
2.3.2 Chance constraint approach
We now examine the FBQ model with chance constraints. Identical to Section 2.2.2, we
assume Pr[st+1 > rt+1|xt] ≤ αR for all t. Assuming t is a bioreactor adjustment decision
epoch, we modify the chance constraint associated with the bioreactors as follows:
Pr[st+τ > b
0
t+τ |xt] ≤ αB
for τ = 1, ..., T . Thus the choice of qt must ensure these chance constraints hold until the
next epoch when bioreactor readjustment is permitted.
We now consider a heuristic that considers only a single bioreactor adjustment period.
Without loss of generality, assume bioreactor readjustment occurs at epoch t = 1. Thus,
at epoch 1, the design phase, the fixed total number of bioreactors is determined over the
finite planning horizon and the first reagent replenishment decision is selected. Then for
epochs t ≥ 2, the operations phase, we determine reagent replenishment decisions at each
epoch. Let x1 = (s1,b1, r1) be a starting state at epoch 1. Then, the optimality equation
for the FBQ design phase is
v1(x1) = min
0 ≤ m1 ≤ min{s1, b01, r1}
q1 ≥ −(b01 −m1 + b11), a1 ≥ 0
E{C̃(q1, a1,m1, d1|x1) + βv2(x2)} (FBQ-c-d)
s.t. Pr[st+1 > b
0
t+1|x1] ≤ αB, ∀t = 1, ..., T ,
P r[s2 > r2|x1] ≤ αR.
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For t = 2, ..., T , the optimality equation for the FBQ operation phase is
vt(xt) = min
0≤mt≤min{st,b0t ,rt},at≥0
E{C̃(0, at,mt, dt|xt) + βvt+1(xt+1)} (FBQ-c-o)
s.t. Pr[st+1 > rt+1|xt] ≤ αR,
and vT +1(xT +1) = 0 is the boundary condition. The FBQ-c-d and FBQ-c-o problems




1 be the initial
total bioreactor quantities (either busy or idle). Then B = B1 + q1 is the total number
of bioreactors after adjustment q1, a number that will remain fixed over the remainder
of the planning horizon. Similar to the ABQ model, it is straight forward to show m∗t =
min{st, b0t , rt}. Therefore, we letmt = min{st, b0t , rt} in the FBQ-c models, which reduces
the number of decision variables from three to two.
The FBQ-c problem can be solved using a two-step method:
Step 1. Given a bioreactor adjustment decision q1, and for the moment ignoring the chance
constraints Pr[st+1 > b0t+1|x1] ≤ αB, we solve FBQ-c-d and FBQ-c-o and obtain optimal
reagent replenishment policies a∗. The minimized total cost for a given design q1 is
u(x1, q1) = min
a1≥0
E{C̃(q1, a1,m1, d1|x1) + βv2(x2)}
s.t. Pr[s2 > r2|x1] ≤ αR.
Step 2. We then seek an optimal q1 that satisfies Pr[st+1 > b0t+1|x1, q1, a∗] ≤ αB for
t ∈ [T ], and produces the minimum total cost u(x1, q1).
In Step 1, an optimal reagent replenishment policy is separable from the bioreactor
adjustment decision and has a simple analytical form.
Proposition 2.3.1. Given q1 and qt = 0 for all t ≥ 2, an optimal reagent replenishment
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policy for FBQ-c is to replenish
a∗(xt) = (st + F
−1
d (1− αR)− rt)
+,
for t ∈ [T ]. In addition, if A2 holds, an optimal reagent replenishment policy is to replenish
a∗(xt) = st + F
−1
d (1− αR)− rt.
We assume Assumption A2 holds for the remainder of this section. The FBQ-c model
can be rewritten as
v1(x1) = min
q1 ≥ −(b01 −m1 + b11)
E{C̃(q1, a∗(x1), d1|x1) + βv2(x2)} (2.9)
s.t. Pr[st+1 > b
0
t+1|x1] ≤ αB, ∀t = 0, 1, ..., T ,
where for t = 2, ..., T ,
vt(xt) =E{C̃(0, a∗(xt), dt|xt) + βvt+1(xt+1)}
and boundary condition such that vT +1(xT +1) = 0. Let q∗1 the minimum in (2.9). Then
v1(x1) = E{C̃(q∗1, a∗(x1), d1|xt) + βv2(x2)},
and chance constraints Pr[st+1 > b0t+1|x1, q∗0] ≤ αB hold for t ∈ [T ].
Proposition 2.3.2. The policy (q∗1, a∗) is an optimal policy for FBQ-c.
Proof of Proposition 2.3.2 is presented in Appendix A.
Structural properties
We now present two monotonicity results and a lower bound on q∗1 that will lead to an
algorithm for determining q∗1 (Step 2).
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Proposition 2.3.3. For all x1,
(i) Pr[st+1 > b0t+1|x1, q1] is non-increasing in q1 for all t = 1, ..., T .
(ii) E{C̃(q1, a∗(x1), d1|x1) + βv2(x2)} is non-decreasing in q1.
Proof of Proposition 2.3.3 is given in Appendix A. Assuming a lower bound qL on q∗1 ,
Proposition 2.3.3 implies that if we increase q1 incrementally from qL until FBQ-c becomes
feasible, then the first value of q1 that achieves this feasibility is optimal.
We now determine a lower bound qL = qL(x1, αB) on q∗1 . Our lower bound will be such
that
for any q1 < qL(x1, αB), there exists at least one probability among Pr[st+1 > b0t+1|x1, q1]
for t = 1, ..., T that is larger than αB. Let F(k) be the CDF of demands in k consecutive
periods, i.e. F−1(k) (θ) = inf{z : F(k) ≥ θ}. Define qL(x1, αB) := max{q
(k)
1 (x1, αB) : k =
1, ..., T}, where
q
(k)








1 1 ≤ k ≤ T − 1,
s1 + F
−1
(T )(1− αB)−m1 −B1 k = T.
Proposition 2.3.4. The function qL(x1, αB) is a lower bound of q∗1 .
Proof of Proposition 2.3.4 is presented in Appendix A. The next result follows directly
from Proposition 2.3.4.
Corollary 2.3.5. Assuming x1 = (0,0, 0), q
(k)
1 (x1, αB) = F
−1
(k) (1 − αB), and hence




We now present Algorithm 1, which searches for q∗1 by incrementally increasing q1 from
qL(x1, αB) until feasibility is achieved. We now present an approach for determining fea-
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Algorithm 1: FBQ Solver
1 Initialization: set q1 ← qL(x1, αB);
2 Calculate ZR and derive reagent replenishment policy a∗;
3 while maxt∈[T ] Pr[st+1 > b0t+1|x1, q1] > αB do
4 Set q1 ← q1 + 1.
5 end
6 Output: bioreactor adjustment decision q1.
sibility in Algorithm 1 (line 3) and briefly mention search for q∗1 can be accelerated by
revising line 4 in Algorithm 1.
We use the following a Monte Carlo method to validate Pr[st+1 > b0t+1|x1, q1] for a
given bioreactor adjustment decision q1. N instances of T -period simulation paths are
sampled, given x1, q1 and a∗. For the ith instance, define δ(i)[st+1 > b0t+1|x1, q1] = 1 if
st+1 > b
0






is an unbiased estimator of Pr[st+1 > b0t+1|x1, q1].
We consider two validation methods: a Monte Carlo average (MCA) method and a propor-
tional statistical test (PST) method:








(ii) PST: Define the null hypothesisH0 : Pr[st+1 > b0t+1|x1, q1] ≤ αB and its alternative












which can be approximated by a standard normal distribution ([35]; [36]). Let
Ψ−1(θ) be the θ quantile of the standard normal distribution N(0, 1), where θ is a
confidence level. Therefore, we can mark Pr[st+1 > b0t+1|x1, q1] ≤ αB as invalid if
zt+1 > Ψ
−1(θ). We note that the normal approximation in PST would require choos-
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ing N such that min{NαB, N(1 − αB)} ≥ 5 ( [36]). For instance, if αB = 0.05,
N = 100 sample paths are required to perform an adequate PST.
Detailed feasibility checking procedures may refer to Algorithm 3, Appendix B.
There are a variety of techniques for accelerating the search routine in line 4 of Al-
gorithm 1. Given an upper bound of q∗1 , i.e. qU(x1, αB), we can replace the incremental
search with more efficient search algorithms, such as bisection search and golden search.
Since q∗1 is the smallest feasible q1, any feasible q1 is essentially an upper bound of q
∗
1 . A
practical upper bound can be identified utilizing information from an ABQ model. Since
an ABQ model has the adjustability of idle bioreactor quantities, we can run a number of
ABQ simulations to see how many bioreactors would require in the majority of decision
epochs. This range would inform FBQ an upper bound candidate, and by checking its fea-
sibility, we can easily obtain an upper bound of q∗1 . We have also identified an upper bound
that appears always to be feasible in our numerical studies. The construction of this upper
bound and Algorithm details are included in Appendix B.
2.4 Case Study
We now apply our capacity planning models to a supply chain described in [7] and com-
prised of a single CAR-T manufacturing facility, its healthcare network in charge of spec-
imen collections and therapy transplants, and a single reagent supplier. Our CAR-T man-
ufacturing facility model was based on the Clinical Cell and Vaccine Production Facility
(CVPF) at the University of Pennsylvania. Our analysis uses the capacity planning re-
search presented in this chapter and the AuCT-Sim simulation software described in [7].
We adopt system specifications (e.g. demand distribution, production duration, etc.) from
[7], and adopt cost assessments from [14]. System specifications and cost parameters are
summarized in Table 2.1.
The results in this section are based on 400 simulation scenarios. Five ABQ instances
of the number of bioreactors at the facility over the 52-week planning horizon are pre-
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Table 2.1: System specs and cost parameters – Chapter 2 case study
Parameter Fd T T cR hR αR cB hB αB
Type distribution scalar scalar scalar scalar scalar scalar scalar scalar
Value Poisson(4.81) 3 weeks 52 weeks $42,174 $113.5 0.05 $25,000 $14.4 0.05
sented in Figure 2.1 (illustrated by the dotted lines). For the FBQ case, the lower bound
using Proposition 2.3.4 is 21 bioreactors (the blue line in Figure 2.1). Use of Algorithm 1
determined that an optimal number of bioreactors equals 22 (the orange line in Figure 2.1).




























Figure 2.1: Bioreactor quantities versus t
Figure 2.2 illustrates graphically how an optimal number of bioreactors for the FBQ
case can be determined. The x-axis depicts the total number of fixed bioreactors over the
problem horizon, which is varied from 16 to 25. The blue solid line is the discounted
total expected cost. The blue dash-dotted line represents the worst-case bioreactor shortage
probability maxt∈[T ] Pr[st+1 > b0t+1|x1, q1]. The red dash-dotted line is the feasibility
threshold αB = 0.05. The black solid line is the discounted total expected cost for the
ABQ case. We note from Figure 2 that the smallest integer on the x-axis where the blue
dash-dotted line is below the red dash-dotted line is 22.
Comparing reagent inventory levels for the ABQ and FBQ cases, we note that the inven-
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Figure 2.2: Cost and bioreactor shortage probability versus bioreactor quantities
tory replenishment policies are identical: order st minus rt plus a constant that is identical
for both cases. Further, the number of idle bioreactors for the ABQ case does not have
an upper bound on the number of bioreactors that can be added. If, however, the number
of specimens in the queue is large, exceeding the number of idle bioreactors for the FBQ
case, the number of specimens waiting in queue for the FBQ case will exceed the number
of specimens waiting in queue for the ABQ case. Hence, the number of specimens in queue
for the FBQ case will tend to be larger than the number of specimens in queue for the ABQ
case. As a result, reagent replenishment orders for the FBQ case will tend to be larger than
reagent replenishment orders for the ABQ case, as depicted in Figure 2.3. This difference
in part explains why for this case study the cost of ABQ is $2,639,841.96 while the cost of
FBQ is $2,758,403.21, which is 4.3% higher than the ABQ cost.
We now examine the relationship between αB, optimal bioreactor quantity, and total
expected discounted cost. We vary αB between 0.01 and 0.14 in increments of 0.01. As
expected, as αB increases, the optimal number of bioreactors and total expected discounted
cost decrease, as shown in Figure 2.4.
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Figure 2.3: Reagent inventory levels for the first 5 simulations










































Figure 2.4: Optimal bioreactor quantity and total cost v.s. αB
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2.5 Conclusions
We have modeled and analyzed the capacity planning problem of determining the best num-
ber of bioreactors and the best reagent replenishment policy for a cell manufacturing facil-
ity. For the case where the number of idle bioreactors can be adjusted at each epoch, and
for each variant of this case, the penalty cost approach and the chance constraint approach,
we have shown that this number and the reagent replenishment policy are both myopic and
base stock. For the case where the number of bioreactors can only be adjusted periodically,
we have developed near-optimal heuristics for determining the number of bioreactors and
the reagent replenishment policy. A case study based on a CAR-T manufacturing facility
at the University of Pennsylvania was used to demonstrate these results.
We extend our model setting and consider supplier disruption risks in a centralized
manufacturing network in the next chapter.
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CHAPTER 3
RESILIENT CAPACITY PLANNING IN A CENTRALIZED NETWORK UNDER
SUPPLIER DISRUPTION RISKS
In this chapter, we introduce a Capacity Planning (CP) problem in a centralized network
under supplier disruption risks. We define the risk of supplier disruption as the risk of not
getting the full amount of consumables ordered by the fulfillment facility to fulfill build-to-
order/request-to-service demands. We demonstrate problem settings and notations in the
context of autologous cell therapy. Translating all all models, algorithms and results to
other domains are straightforward.
We investigate approaches for determining the number of reusable resources and a re-
plenishment policy for consumable resources for an autologous build-to-order cell therapy
manufacturing system when confronted with supplier disruption risks. We model a supplier
disruption process as an exogenous Markov process. Incidents that cause reagent shortages
include nature disasters, human errors and disease outbreaks. We consider two capacity
planning models, one where the number of bioreactors is adjustable at each decision epoch
and one where this number can only be adjusted periodically. Both models are formulated
as Markov decision process (MDP). We propose algorithms to solve the proposed models.
In the case studies, given different supplier disruption scenarios, we determine the number
of bioreactors and a reagent replenishment policy based in part on data collected from a
CAR-T cell therapy manufacturing facility at the University of Pennsylvania.
The solution of the proposed models introduce a concept of resilient manufacturing.
We compare resilient designs with lean designs in the events of supplier disruptions to
demonstrate costs and benefits of building extra resilience in a centralized network.
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3.1 Introduction
Supplier disruptions in the cell manufacturing industry are of concern for two reasons.
First, patients who qualify for cell therapy often have short term dire prognoses, a sup-
plier disruption can cause a delay in the completion of a cell therapy, and hence a supplier
disruption can significantly increase patient mortality risk. Second, supplier disruptions in
this industry are not uncommon. The cell manufacturing industry is an emerging industry
with an emerging supplier base for certain key reagents, and hence there may be only a
single supplier for a key reagent. Further, the industry is heavily regulated in the U.S. by
the Federal Drug Administration (FDA), and FDA requirements for reagent uniformity and
quality are a challenge to satisfy for a single supplier. Satisfying these requirements for
multiple suppliers would be much more of a challenge. Thus, a typical strategy for miti-
gating supplier disruption risk common in many other industries – sourcing from multiple
suppliers for the same raw material or work in progress – is not common in the cell man-
ufacturing industry. Further, the cell manufacturing industry has witnessed several major
supplier disruptions. In 2017 alone, the cell manufacturing industry witnessed reagent sup-
ply disruptions due to Hurricane Maria, a severe flu season [37, 38], and a shutdown of a
major cell therapy supplier due to sterility issues [39]. More recently, significant reagent
supplier disruption has been caused by the COVID-19 pandemic [40] as demand for several
key reagents [41] needed for COVID-19 antigen testing kits surged, leading to shortages
of those same key reagents for autologous cell therapy manufacturing, shortages that are
forecasted to persist into mid-2021 [42].
The objective of this chapter is to determine good bioreactor adjustment and reagent
replenishment policies for a single cell manufacturing facility subject to supplier disrup-
tion risk. We consider two cases of bioreactor adjustment; adjustment can occur either (i)
at each decision epoch or (ii) periodically. The analytic basis of our research is the infi-
nite horizon expected total discounted cost Markov decision process (MDP). With regard
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to supplier uncertainty, we assume that the maximum number of units of reagent that the
supplier can deliver is a stochastic process described by an exogeneous Markov chain, the
realization of the current maximum value becomes available just before the current epoch,
and all replenishment orders made are fulfilled just before the next epoch. We present exact
and heuristic algorithms to solve the proposed models. Given different supplier disruption
scenarios, we illustrate our results by determining optimal (or near-optimal) bioreactor ad-
justment and reagent replenishment policies based in part on data collected from a CAR-T
cell therapy manufacturing facility at the University of Pennsylvania. If reagent avail-
ability is completely certain in the future, we determine lean bioreactor adjustment and
reagent replenishment policies. This special case of our model serves as a benchmark for
determining the additional cost of (necessarily resilient) bioreactor adjustment and reagent
replenishment policies when future supply availability is uncertain.
The usefulness of these results is two-fold. First, the results can provide useful man-
agerial insights to the manager of a cell manufacturing facility. Second, the results can help
improve the usefulness of much more detailed and realistic simulation models (see [7] for
example) by significantly reducing simulation run time and computational effort.
3.1.1 Literature review
A review of how supply chain disruptions can be mitigated for a single production facility
is presented in [9], where three distinct risk mitigation strategies are considered: inven-
tory redundancy, the use of multiple suppliers, and product substitution. We focus on
inventory redundancy since the autologous cell manufacturing industry invariably relies on
single suppliers for key reagents for reasons given above and product substitution is not a
possibility. We assume that inventory is periodically reviewed, a common practice in the
industry. Continuous review models are surveyed in [9].
Periodic review inventory redundancy models fall into two categories, which we de-
scribe following several definitions. AssumeAt is the maximum number of units of reagent
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that the supplier can deliver before epoch t + 1, is the order size at epoch t, and αt is the
order received just before epoch t+ 1.
• Category 1: assumes that the process {At, t ≥ 1} is described by an exogenous
Markov chain governed by the probability Pr(At+1|At), the realization of At be-
comes available to the decision maker just before epoch t, at ≤ At, and αt = at
for all t. Thus, the decision maker knows the maximum amount of reagent the sup-
plier can deliver before placing a replenishment order, and assuming the order placed
satisfies this constraint, the order is guaranteed to be fulfilled before the next epoch.
This first category is assumed throughout this paper.
• Category 2: assumes At is infinite for all t and that Pr(αt|at) is given. Thus, the
decision maker can place a replenishment order of any size but is not guaranteed that
the order placed will be the order received.
Several special cases of Category 1 have appeared in the literature; we present three
general cases. First, we consider suppliers that are either ‘on’ with infinite capacity or ‘off’
(totally disrupted) with zero capacity, which we call ‘on-off’ suppliers. A finite-horizon
inventory control problem with stationary random demand, zero lead time, backlogging
demand, and geometric disruption duration (two-state Markov chain of supplier availabil-
ity) is considered in [43], which assumes that the current supplier state is unknown but can
be inferred from the previous supplier state. An (s, S) type policy is proven to be optimal
when a fixed cost is assessed when placing an order, where s depends on the supplier state
of the previous period; however, S is assumed to be independent of the previous supplier
state. This model is generalized in [44] to the case where the unit ordering cost is stochastic
and also extended to a perishable inventory control case with infinite horizon, deterministic
demand, and backlogging. In [45] an ‘on-off’ disruption models random transportation
delays with an exogenous Markovian process modeling the pipeline of in-transit replenish-
ment. The authors consider stationary random demand and backlogging demand and prove
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that a base-stock policy is optimal if there is no fixed cost and an (s, S) policy is optimal
when a fixed cost exists. This result is applied to a port-of-entry supply disruption in [46].
Supplier disruption in [47] is modeled as a state dependent Bernoulli process. Given the
state of supplier disruption, the availability of the supplier in the next period is a Bernoulli
process whose parameter is state dependent, e.g. age of the current supplier disruption. Sta-
tionary random demand is assumed with lost-sales, and bounds are presented for myopic
and look-ahead heuristics.
As a second example of Category 1, inventory control with fixed supplier capacity has
been well studied. Finite and infinite horizon inventory control problems with stationary
and backlogging demand, linear ordering cost, and finite positive supplier capacity are
considered in [48, 49]. Results in [48, 49] show that an optimal inventory control policy
is a modified base-stock policy: when the initial stock is below the base-stock level, the
inventory is stocked up to the base-stock level, or as close to it as possible (given the
limited capacity); otherwise, order nothing. The finite horizon model in [49] is extended in
[50] to consider fixed ordering costs. It is shown that (s, S) policies may not be optimal and
that there exists an optimal policy that is an X − Y band type of policy: order the capacity
when the initial stock is below X , and order nothing when the initial stock is above Y . If
the initial stock is between X and Y , the optimal ordering quantity is problem-dependent,
which requires an iterative method to solve the dynamic program. However, the X − Y
band structure significantly reduces the computational demands of the dynamic program.
An extension of this model to an infinite horizon is presented in [51]. Key results of [51]
are: (i) an X − Y band type policy is optimal; (ii) the difference Y − X ≥ 0 is no more
than one unit of the supplier capacity. Similar results are also presented in [52].
As a third example of Category 1, disruption risks can also be modeled as a supplier
with dynamic limited supply capacity. In [53] a model is presented that considers situa-
tions where supplier capacities at decision epochs are exogenous independent identically
distributed random variables (IID). Stationary random backlogging demand is considered
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in both finite and infinite period problems. It is shown that the cost-to-go functions (includ-
ing the single period cost) may not be convex but are quasi-convex (convex on the left-hand
side of the minimum, and nondecreasing on the right-hand side of the minimum). Thus, a
base-stock policy is optimal. In the infinite horizon setting, it is shown that the structure of
an optimal order policy is an extended myopic policy, requiring the consideration of review
periods of uncertain length. Similar results are presented in [54]. The model of disruption
risk presented in this paper extends the model considered in [53] to the case where the
supplier capacities are described as an exogenous Markov chain.
With respect to Category 2, a comprehensive review of random yield is presented in
[55]. Models using a yield rate are considered in [56, 57, 58, 59]. Many yield rate mod-
els assume αt = atU , where U is a random variable with given cumulative distribution
function that is independent of at. For finite and infinite horizon problems with convex
holding/penalty cost functions, a base-stock policy can be shown to be optimal; however,
the base stock level is problem dependent. For stationary random and backlogging de-
mand, the calculation of optimal base-stock levels is discussed in [58, 59]. Binomial yield
is analyzed in [60] and considers stationary or cyclic demand with demand backlogging.
A generic probabilistic modeling of random yield is presented in [61], where supplier un-
certainty is modeled by P (αt|at) and demand is assumed to be deterministic and can be
backlogged. Conditions for the existence of an optimal policy that has a ‘staircase’ struc-
ture are presented, and this structure is shown to be computationally useful.
We are unaware if combinations of Categories 1 and 2 have been addressed in the
literature, several of which would represent interesting directions for future research.
3.1.2 Organization
This chapter is outlined as follows. Section 3.2 presents the adjustable bioreactor quantity
(ABQ-sdr) model. We show that an optimal bioreactor adjustment and a reagent inventory
control polices are base-stock type. There exists a myopic base-stock policy to be opti-
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mal for bioreactor adjustment. We discuss the computation of optimal and near-optimal
reagent inventory policies. In Section 3.3, we present the fixed bioreactor quantity (FBQ-
sdr) model. The convexity of total cost in the number of bioreactors guarantee the existence
of an efficient search algorithm to determine an optimal bioreactor quantity. Case studies
of the CAR-T cell therapy facility in the University of Pennsylvania is revisited in Section
3.4 given variant supplier disruption scenarios. Section 3.5 concludes this chapter.
3.2 Adjustable Bioreactor Quantity Model with Supplier Disruption Risks (ABQ-
sdr)
3.2.1 Model formulation
We now present an infinite horizon total discounted cost Markov Decision Process (MDP)
model of the reagent replenishment and bioreactor quantity selection processes. We assume
that reagent replenishment and idle bioreactor adjustment decisions made at epoch t can be
fulfilled before epoch t+ 1, an assumption made for model simplicity and tractability. The
level of realism of this assumption is situation dependent. Typically, periodic review in this
industry occurs weekly and the time between order placement and order receipt for reagent
replenishment may take longer than one week. With respect to idle bioreactor adjustment,
this assumption may be realistic if the facility manufactures several cell therapies, the biore-
actors needed for each cell therapy are interchangeable, and there is a substantial number
of ’buffer’ bioreactors in the facility. However, for a facility that manufactures only a single
therapy, the total number of bioreactors at the facility would likely be a capital expenditure
decision more realistically determined over a longer than one week period, e.g., quarterly,
every 6 months, annually, a situation that we consider later in this chapter. In any case, the
solution to this problem will be useful in addressing a key capacity planning question: How
many bioreactors are needed and what is a good reagent replenishment policy for therapy
production in light of supplier disruption risks?
We now present the adjustable bioreactor quantity model with supplier disruption risks
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(ABQ-sdr). Assume at decision epoch t that
• st ≥ 0 is the number of specimens in the arrival queue, waiting for therapy manufac-
turing to begin
• bτt ≥ 0 is the number of bioreactors that are τ epochs from completing the manufac-
turing process. Let bt = (b0t , ..., b
T−1
t ), where T is the production time required and
b0t is the number of idle bioreactors
• rt ≥ 0 is the number of units of reagent in stock. We consider a unit of reagent to be
a collection of the multiple reagents needed to complete the production of a therapy
• 0 ≤ mt = min{st, b0t , rt} is the number of therapies starting at time t. A patient’s
therapy production can only begin if the patient’s specimen is in the arrival queue and
there is an idle bioreactor and one unit of each type of reagent at the manufacturing
facility that can be assigned to the specimen.
Further, assume
• dt is the number of specimens that arrive between epoch t and epoch t + 1. We
assume that the stochastic process {dt, t ≥ 0} is a sequence of independent, iden-
tically distributed distributed random variables with known cumulative distribution
function F , where the realization of dt becomes available to the decision maker just
before epoch t+ 1. We assume E[dt] <∞;
• qt, a decision variable, is the idle bioreactor adjustment, which is determined at epoch
t, and added or subtracted from the system before epoch t+ 1;
• at ≥ 0, a decision variable, is the number of units of reagent ordered at epoch t and
received before epoch t+ 1;
• At ≥ 0 is the maximum units of reagent that can be supplied to the manufacturing
facility at epoch t. The dynamic of the process {At, t ≥ 0} is described by the epoch
and action invariant Markov chain Pr(At+1|At).
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Let xt = (st,bt, rt, At) be the system state at epoch t. We assume qt and at are determined
based on knowledge of xt. The resulting system dynamics are:
st+1 = st −mt + dt,
bτt+1 =

b0t −mt + b1t + qt τ = 0,
bτ+1t 1 ≤ τ ≤ T − 2,
mt τ = T − 1,
rt+1 = rt −mt + at,
P r(At+1|At),
from which we obtain an updated system state xt+1. Since the number of idle bioreactors
is non-negative, qt ≥ −(b0t − mt + b1t ), where b0t − mt + b1t is the maximum number of
bioreactors that can be removed from the system. In addition, 0 ≤ at ≤ At.
Assume the single period cost accurred between epoch t and t+ 1 are as follows:
• cRat is the reagent replenishment cost for the reagent, where cR is the cost per unit
of regent
• cBqt is the bioreactor adjustment cost, where cB is the cost or savings per bioreactor,
depending on whether qt is positive or negative
• hR(rt+1 − st+1)+ is the random variable holding cost for the reagent, charged only
if there are more units of reagent than specimens at epoch t + 1, where hR is the
holding cost per unit of reagent
• hB(b0t+1 − st+1)+ is the random variable bioreactor holding cost, charged only if
there are more bioreactors than specimens at epoch t+ 1, where hB is the bioreactor
holding cost per bioreactor
• pR(st+1− rt+1)+ is the random variable penalty for having an insufficient number of
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units of reagent in order to start therapy manufacturing for all specimens that have
arrived at the facility and are waiting for therapy production to begin
• pB(st+1 − b0t+1)+ is the random variable penalty for having an insufficient number
of idle bioreactors in order to start therapy manufacturing for all specimens that have
arrived at the facility and are waiting for therapy production to begin.
We now present the optimality equation for ABQ-sdr, assuming an infinite horiozon
total discounted cost MDP model with discount factor β ∈ [0, 1]. Let
[Hv](xt) = min
qt ≥ −(b0t −mt + b1t ),
0 ≤ at ≤ At
E{C(qt, at, dt|xt) + βv(xt+1)} (ABQ-sdr)
where
C(qt, at, dt|xt) =cRat + hR(rt+1 − st+1)+ + pR(st+1 − rt+1)+
+ cBqt + hB(b
0
t+1 − st+1)+ + pB(st+1 − b0t+1)+
is the single period cost function. Results in [32] guarantee the existence of a unique fixed
point v∗ such that limn→∞ ‖vn− v∗‖ = 0, where {vn} is such that v0 = 0, vn+1 = Hvn for
all n, and ‖ · ‖ is the sup-norm. Further, a policy that achieves the minimum in Hv∗ is an
optimal policy. Our objective is to determine an optimal or near-optimal policy.
3.2.2 A simplifying transformation
Let zt = qt + b0t + b
1
t and yt = at + rt, and define an operator H̄ as follows
[H̄w](xt) = min
zt ≥ mt,
rt ≤ yt ≤ rt +At
E{G(zt, yt, dt|xt) + βw(xt+1)}, (3.1)
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where
G(zt, yt, dt|xt) =(1− β)cBzt + hB(zt − st − dt)+ + pB(st + dt − zt)+
+ (1− β)cRyt + hR(yt − st − dt)+ + pR(st + dt − yt)+.
We show that (ABQ-sdr) and (3.1) are optimal policy invariant by constructing a shaping
function [62]





cBmt+n−(T−1) + (cR + cB)E{dt}
}
,
so that G(zt, yt, dt|xt) = C(zt − b0t − b1t , yt − rt, dt|xt) + φ(xt)− βφ(xt+1), and w(xt) =
v(xt)− φ(xt). It follows that w∗ = v∗ + φ is the unique fixed point of H̄ and a policy that
is optimal for (3.1) is optimal for (ABQ-sdr) and conversely. Thus, in seeking an optimal
policy, it is sufficient to analyze the operator H̄ . Let
g(zt, yt|xt) = E{G(zt, yt, dt|xt) + βw(xt+1)}.
Lemma 3.2.1. g(zt, yt|xt) is convex in zt and yt.
A proof of Lemma 3.2.1 is presented in Appendix A. The existence of a base-stock type
policy is a direct result of Lemma 3.2.1.
Proposition 3.2.2. There exists an optimal policy for ABQ-sdr that is base-stock, and hence
there exist two state dependent critical values, z∗(xt) and y∗(xt), such that optimal actions
in epoch t are
q∗(xt) = z
∗(xt)− b0t − b1t , a∗(xt) = min{(y∗(xt)− rt)+, At}.
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3.2.3 Attainability
We now present conditions that guarantee the existence of an optimal policy that is base-
stock and myopic. Let
G(zt, yt, dt|xt) = Gz(zt, dt|xt) +Gy(yt, dt|xt),
where
Gz(zt, dt|xt) = (1− β)cBzt + hB(zt − st − dt)+ + pB(st + dt − zt)+,
Gy(yt, dt|xt) = (1− β)cRyt + hR(yt − st − dt)+ + pR(st + dt − yt)+.




















F−1(ρ) = inf{x : F (x) ≥ ρ}.
Since mt ≤ st, the following lemma holds trvially.
Lemma 3.2.3. z̄(st) ≥ mt for all t.
The next result follows directly from Lemma 3.2.3, which illustrate the attainability for
bioreactor adjustment.






We next show that the bioreactor control and reagent control can be decoupled. Proof
of Proposition 3.2.5 is presented in Appendix A.
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. Then, (z̄, ỹ) is an optimal policy for ABQ-sdr.
Propositions 3.2.4 and 3.2.5 indicate the optimality the myopic bioreactor adjustment
policy, i.e. z∗ = z̄. Let ȳ(st)) minimize E[Gy(yt, dt|xt)] with respect to yt. Then, ȳ(st) =
F−1(ρ̄R) + st, where ρ̄R =
pR−(1−β)cR
pR+hR
. The following result provides sufficient conditions
for rt ≤ ȳ(st) ≤ rt + At for all t ≥ 1; see proof in Appendix A.
Lemma 3.2.6. Assume r1 ≤ ȳ(s1) ≤ r1 + A1 and Pr(dt ≤ At) = 1 for all t. Then,
rt ≤ ȳ(st) ≤ rt + At for all t.
We define Condition 1 as follows.
Condition 1. (C1) r1 ≤ ȳ(s1) ≤ r1 + A1 and Pr(dt ≤ At) = 1 for all t.
(C1) is the attainability condition for reagent replenishment, and the next result follows
directly from Lemma 3.2.6.







Propositions 3.2.4, 3.2.5 and 3.2.7 indicate the following Corollary.
Corollary 3.2.8. Assume r1 ≤ ȳ(s1) ≤ r1 + A1 and Pr(dt ≤ At) = 1 for all t. Then,
(z̄, ȳ) is an optimal policy for ABQ-sdr.
3.2.4 Bounds
We obtain a myopic policy by solving a single period problem
min
zt ≥ mt,
rt ≤ yt ≤ rt +At
E{G(zt, yt, dt|xt)}. (3.2)
A myopic reagent replenishment policy is ȳ(st) = F−1(ρ̄R) + st. The myopic base-stock
level is affine in st and is independent of At. The myopic policy is a idealistic policy
assuming there are no or negligible supplier disruption risks.
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In contrast idealistic planner, a pessimistic planner at the epoch t makes the decisions
as if the supplier would be totally disrupted in the following periods. Define a pessimistic
single period function
















and a pessimistic policy is obtained by solving an pessimistic simple period problem
min
zt ≥ mt,
rt ≤ yt ≤ rt +At
E{J(zt, yt|xt)}. (3.3)
We remark that J is convex in zt and yt, and therefore, there also exists an base-stock policy







βk[−pR + (pR + hR)F(k+1)(yt − st) ≥ 0
}
,
where F(k) is the convoluted distribution of i consecutive periods’ demand.
We now consider (C1) does not hold, and present bounds of optimal reagent base-stock
level y∗. Proof of Proposition 3.2.9 can be found in Appendix A.
Proposition 3.2.9. ȳt(st) ≤ y∗(xt) ≤ ŷt(st).
3.2.5 Solution algorithm
We now introduce an accelerated algorithm to solve (3.1). We consider two acceleration
methods.
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• Action elimination: the action space of yt is reduced to
[max{ȳt, rt},min{ŷt, rt + At}]
• Reduced-space reformulation: substituting z∗t (xt) = z̄(st) = F−1(ρ̄B) + st in the
state dynamic equation, we have b0t+1 = st−mt +F−1(ρ̄B). Therefore, (st, b0t , rt) is
a sufficient statistic. Define
v−(x−t ) = min
max{ȳt,rt}≤yt≤min{ŷt,rt+At}
E{G−(yt, dt|x−t ) + βv−(x−t+1)}, (3.4)
where
G−(yt, dt|x−t ) =(1− β)cB(F−1(ρ̄B) + st) + hB(F−1(ρ̄B)− dt)+ + pB(dt − F−1(ρ̄B))+
+ (1− β)cRyt + hR(yt − st − dt)+ + pR(st + dt − yt)+.
We note that (3.4) has a reduction of T − 1 dimension in its state space, which
would accelerate the speed of iterative methods by reducing the number of cost-to-
go function evaluations. Value/policy iteration algorithms can be applied to obtain
an optimal base-stock level for any given reduced state x−t , which is also optimal to
all xt’s which can be reduced to x−t .
3.3 Fixed Bioreactor Quantity Model with Supplier Disruption Risks (FBQ-sdr)
3.3.1 Model formulation
We now consider the case where the number of bioreactors can only be readjusted periodi-
cally, i.e. every T epochs, rather than at each epoch (the T = 1 case). We expect T to be
significantly larger than T . For example, assume the time between decision epochs is one
week, three weeks are required to manufacture a therapy, and the number of bioreactors
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can be adjusted yearly. Then, T = 3 and T = 52. We refer to this problem as the fixed
bioreactor quantity model with supplier disruption risks (FBQ-sdr).
Let the operator H̄ be defined as
[H̄v](xt) = min
0≤at≤At
E{C(0, at, dt|xt) + βv(xt+1)}.
Define the sequence {vτ,n} as:
vτ,n(xt) = [H̄vτ+1,n](xt), 2 ≤ τ ≤ T ,
v1,n(xt) = [Hv2,n](xt),
(FBQ-sdr)
vT +1,n+1 = v1,n, and assume vT +1,0 = 0. Results in [32] imply that there exists a set
{vτ , τ = 1, ..., T + 1} such that this set is the unique solution to v∗τ = H̄v∗τ+1 for τ =
2, ..., T , v∗1 = Hv∗2 , and v∗1 = v∗T +1, and limn→∞ ‖vτ,n − v∗τ‖ = 0 for τ = 1, ..., T + 1,
where ‖ · ‖ is the sup-norm. Further, a policy π∗τ that achieves the minimum in H̄vτ+1 for
τ = 2, ..., T and the minimum in Hv2 for τ = 1 is an optimal policy.
3.3.2 Solution algorithm and bounds
The optimal policy structure in Proposition 3.2.5 does not extend to the T > 1 case. This
loss of structure and the resulting computational burden of determining an optimal policy
for FBQ-sdr motivate interest in examining heuristic procedures. Consider the following
easily implemented procedure for determining a near-optimal policy for FBQ-sdr. Given a
state xt, we adopt the reagent replenishment policy of ABQ-sdr, i.e. y∗(xt), and replenish
ã(xt) = (y
∗(xt)− st)+. Given this policy, for 2 ≤ τT , let
ṽτ,n(xt) = E{C(0, ã(xt), dt|xt) + βṽτ+1,n(xt+1)},
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while determine the bioreactor adjustment quantity by solving
ṽ1,n(xt) = min
qt≥−(b0t−mt+b1t )
E{C(qt, ã(xt), dt|xt) + βṽ2,n(xt)}.
Thus, there exists a unique set {ṽ∗τ , τ = 1, ..., T + 1} such that ṽ∗1 = ṽ∗T +1,
ṽ∗τ (xt) = E{C(0, ã(xt), dt|xt) + βṽ∗τ+1(xt+1)},
for 1 ≤ τ ≤ T + 1, and
ṽ∗1(xt) = min
qt≥−(b0t−mt+b1t )
E{C(qt, ã(xt), dt|xt) + βṽ∗τ+1(xt+1)}.
Let the heuristic policy for adjusting the number of bioreactors achieve the above minimum.
We now present a bound result.
Proposition 3.3.1. Upper and lower bounds of optimal value functions
v∗(xt) ≤ v∗τ (xt) ≤ ṽ∗τ (xt), 1 ≤ τ ≤ T + 1,
where v∗ is the fixed point of H and the optimal value function for ABQ-sdr.
v∗(xt) is a lower bound since ABQ-sdr is a relaxation of FBQ-sdr by allowing biore-
actor adjustment at each decision epoch. ṽ∗τ (xt) is a upper bound since ã(xt) is a feasible
policy.
3.4 Case studies
We now apply our capacity planning models to a supply chain described in [7] and com-
prised of a single CAR-T manufacturing facility, its healthcare network in charge of spec-
imen collections and therapy transplants, and a single reagent supplier. Our CAR-T man-
ufacturing facility model is based on the Clinical Cell and Vaccine Production Facility
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(CVPF) at the University of Pennsylvania. We adopt system specification (e.g. demand
distribution, production duration, etc.) from [7], and adopt cost assessments from [14].
The penalty costs are carefully evaluated using system simulations (see [7]) to ensure high
Table 3.1: System specs and cost parameters – Chapter 3 case study
Parameter Fd T T cR hR pR cB hB pB
Type distribution scalar scalar scalar scalar scalar scalar scalar scalar
Value Poisson(4.81) 3 weeks 52 weeks $42,174 $113.5 $121,106.3 $25,000 $14.4 $70,383.04
service levels. Two case studies are included in this section. The first study compares
ABQ-sdr and FBQ-sdr to demonstrate the use of the models. The second study compares
FBQ-sdr and a risk-free FBQ model to demonstrate cost and benefit of building extra re-
silience into the manufacturing network.
In both case studies, we investigate a 52-week planning horizon, and consider a sim-
plified supplier disruption process with two states – undisrupted (At = ∞) and disrupted
(At = 0) with supplier state transition matrix shown below.
At =∞ At = 0
At =∞ 1− εd εd
At = 0 εu 1− εu
εd is the probability that a supplier transits from an undisrupted state to a disrupted state,
and εu is the probability that a supplier transits from a disrupted state to an undisrupted
state. The supply disruption process is a two-state Markov process whose parameters,
i.e. εd and εu, are generally referred to as the disruption and recovery probabilities (see
[9]). We adopt this supply process modeling as [9] and references therein argue that ”this
simple supply model is flexible enough to accommodate a spectrum of disruption profiles”.
Indeed, frequency of occurrence of the supplier disruption is characterized by εd; a larger εd
indicates a more frequent disruption. On the other hand, duration of the supplier disruption
is correlated with εu; a smaller εu suggests longer supply outage.
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3.4.1 Case study 1: supplier disruption risk mitigation using ABQ-sdr and FBQ-sdr
models
We now demonstrate the use of ABQ-sdr and FBQ-sdr models under four supplier disrup-
tion profiles:
I. Infrequent and long disruptions: small εd and εu
II. Infrequent and short disruptions: small εd and large εu
III. frequent and long disruptions: large εd and small εu
IV. frequent and short disruptions: large εd and εu.
Parameter values are summarized in Table 3.2.
Table 3.2: Disruption parameters summary
Instance I II III IV
εd 0.1 0.1 0.9 0.9
εu 0.1 0.9 0.1 0.9
Test results in this section are based on 400 simulation scenarios. Five ABQ-sdr in-
stances of the number of bioreactors at the facility over the 52-week planning horizon are
presented in Figure 3.1 (illustrated by the dotted lines). For the FBQ-sdr models, the opti-
mal number of bioreactors are illustrated by the solid line in Figure 3.1. When bioreactor
is adjustable, idle bioreactors are stocked up when long disruptions occurred, and are out-
let after the disruption. Otherwise, the total bioreactor quantities stays with in a range
of [15, 25]. When bioreactor adjustment is fixed, an excessive number of bioreactors are
kept to handle the specimen queue accumulated during the supplier disruptions. Figures
3.1a and 3.1c suggest 3 times more bioreactor when disruptions are expected to be long
(10 weeks in expectation) comparing to Figures 3.1b and 3.1d when supplier disruptions
are short (1.1 weeks in expectation). Moreover, FBQ-sdr suggests more bioreactors when
supplier disruptions are more frequent.
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(a) Infrequent and long disruptions



























(b) Infrequent and short disruptions

























(c) Frequent and long disruptions



























(d) Frequent and short disruptions
Figure 3.1: Bioreactor quantities v.s. t
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Comparing reagent inventory levels for ABQ-sdr and FBQ-sdr cases, we observe that
the more frequent and longer supplier disruptions are expected, the more units of reagent
are ordered from the supplier. Further, since the number of idle bioreactors for the ABQ-
sdr model does not have an upper bound on the number of bioreactors that can be added. If
the specimen queue is long, exceeding the number of idle bioreactors for the FBQ-sdr case,
the number of specimens waiting in queue for the FBQ-sdr case will tend to be larger than
the number of specimens in queu for the ABQ-sdr case. As a result, reagent replenishment
orders for the FBQ-sdr case will tend to be larger than reagent replenishement orders for
the FBQ-sdr case, as depicted in Figure 3.2. Statistics of system state are summarized in
Table 3.3.
Table 3.3: System state statistics
Bioreactor Quantity
εd εu Avg. Max.
Avg. Reagent Inv. Lvl. Avg. Specimen Queue Length
ABQ-sdr
0.1 0.1 28.14 264 37.60 15.18
0.1 0.9 18.11 40 10.40 4.86
0.9 0.1 26.20 279 55.79 16.01
0.9 0.9 19.06 42 14.15 4.98
FBQ-sdr
0.1 0.1 69 38.44 16.02
0.1 0.9 22 10.43 4.88
0.9 0.1 71 56.53 17.76
0.9 0.9 22 14.16 5.02
3.4.2 Case study 2: cost and benefit of resilience
In this case study, we first introduce a definition of cost/benefit ratio, R. Then report a
heatmap ofR to assist capacity planner in evaluating the cost and benefit of building extra
resilience into the manufacturing network.




βt−1[cRat + hR(rt+1 − st+1)+ + cBqt + hB(b0t+1 − st+1)+]
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(a) Infrequent and long disruptions
























(b) Infrequent and short disruptions



























(c) Frequent and long disruptions

























(d) Frequent and short disruptions
Figure 3.2: On-hand reagent v.s. t
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be an discounted total accounting cost, which includes purchasing and holding costs of




βt−1[pR(st+1 − rt+1)+ + pB(st+1 − b0t+1)+]
be an discounted total penalty cost. Using the penalty cost FBQ model in Chapter 2 as
a baseline, a risk-ignored capacity planner determine actions {qt, at}t∈T with the myopic
replenishment policy z̄ and ȳ. Let ΩFBQa and Ω
FBQ
p be accounting cost and penalty cost
of an FBQ model, and ΩFBQ−sdra and Ω
FBQ−sdr
p be accounting cost and penalty cost of an





which measures the accounting cost increment per dollar value saved for the penalty cost.
We variate εd and εt from 0.05 to 0.95 with a step size of 0.05. Test results are calculated
based on 400 simulations for each supplier disruption profile. Account cost increment and
penalty reduction are illustrated in Figure 3.3. FBQ-sdr model reports larger accounting
cost increment if supplier disruptions are liekly to be more frequent and longer, see Figure
3.3a. On the other hand, the penalty cost is more significant if supplier disruptions are
liekly to be more frequent and longer, see Figure 3.3b.
A heatmap of R is depicted in Figure 3.4. When supplier disruption is infrequent (i.e.
εd close to 0) and short (i.e. εu close to 1), building up extra resilience is less beneficial.
However, if disruption is more frequent (i.e. larger εd) and longer (i.e. smaller εu), building



































































































































































(b) Penalty cost reduction

















































































Figure 3.4: Cost/benefit ratio of resilience
3.5 Conclusion
We have modeled and analyzed the capacity planning problem under supplier disruption
risk to determine the best number of bioreactors and the best reagent replenishment policy
for a cell manufacturing facility. For the case where the number of idle bioreactors can be
adjusted at each epoch, we show that there exist a myopic bioreactor adjustment policy to
be optimal, while the optimal policy of reagent replenishment will not be myopic. We have
developed optimal and near-optimal algorithms to solve this problem. For the case where
the number of bioreactors can only be adjusted once, we have developed near-optimal
heuristics to determining the number of bioreactors and the reagent replenishment policy.
Case studies based in part on data collected form a CAR-T cell therapy manufacturing
facility at the University of Pennsylvania are studied demonstrate these results.
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CHAPTER 4
RESILIENT CAPACITY PLANNING IN A DECENTRALIZED NETWORK
UNDER SUPPLIER DISRUPTION RISKS
In this chapter, we investigate a capacity planning problem in a decentralized network under
supplier disruption risks. Our research is motivated by the emerging need to decentralize a
cell therapy manufacturing facility to increase customer access and reduce therapy fulfill-
ment leadtime [7].
We consider two kinds of decentralized networks. The first network has isolated re-
gional facilities (Iso-Net), while the second network has coordinated regional facilities
(Co-Net). In an Iso-Net, each facility fulfills its regional demand with its own capacity;
while in a Co-Net, all facilities coordinate by sharing demand and transshipping resources
(bioreactor and reagent). The second supply chain is reconfigurable as production capaci-
ties in different facilities are dynamically adjustable.
A key concept we propose in this chapter is dynamic resilience. We show that a coordi-
nating and reconfigurable decentralized network exhibit greater resilience with lower costs
when confronted with supplier disruption risks. In this chapter, we model the two decen-
tralized networks, Iso-Net and Co-Net, and introduce computational challenges of solving
these models, which motivate our research in design of efficient and effective heuristic al-
gorithms. In the case studies, we construct a hypothetical decentralized network based in
part on data collected from a CAR-T cell therapy manufacturing facility at the University
of Pennsylvania. We compare decentralized models and different heuristic polices based
on the constructed decentralized network. Testing results suggest that instead of increasing
resource redundancy in all facilities, it is beneficial to only restore limited level of redun-
dancy and adaptively reconfigure the network.
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4.1 Introduction
Since the approvals of several CAR-T therapies, the public education and awareness of
these advanced medicines boosted the demands of autologous cell therapies. A centralized
manufacturing network has less demanding regulatory requirements, greater potential for
economies of scale, greater consistency in operations, but less patient access and longer
fulfillment time. A decentralized network is able to manufacture cell therapies closer to
the demand locations, resulting in higher patient access, shorter fulfillment time, fewer
transportation and storage of work-in-processes, and less handling and packaging. The
emerging need for decentralized networks is motivated by the necessity to improve patient
service quality.
Supplier disruption risks, introduced in Chapter 3, is also a major challenge for any
decentralized manufacturing network. Supply chain resilience can be strengthened by, for
example, increasing the inventory levels of raw material, work-in-progress, and the final
product and/or adding manufacturing and/or storage capacity. However, such procedures
for strengthening supply chain resilience and agility also can be expensive. Competitive
advantage is enhanced if a firm’s supply chain resilience and agility are at least as good
as the competition’s but at lower cost. Different from handling reagent supplier disruption
in a centralized facility (see Chapter 3), a decentralized network can rebalance specimen
and reagent inventories among facilities. Supply chain resilience can be further enhaced
by also relocate manufacturing modules (e.g. bioreactors) based on real-time data-driven
demand analysis. The reconfigurability of a decentralized network could blend the advan-
tages of a distributed supply chain system of easy customer access and fast fulfillment, and
a centralized supply chain system to enable economies of scale, resource risk ”pooling”
and cost reduction. Therefore, we propose a dynamic resilient decentralized manufactur-
ing network for autologous cell therapy (and other build-to-order products) which allows
the supply chain system to respond to and recover from supplier disruptions by sharing
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demand, transshipping inventory and relocating manufacturing capacities where needed in
the network. Such a reconfigurable supply chain will be dynamically resilient and either
lean or agile, depending on need.
The objective of this chapter is to investigated ways to reduce the cost of supply chain
resilience in a decentralized autologous cell therapy manufacturing network under sup-
plier disruption risks. We propose analytical and numerical methods for determining (i)
the bioreactor quantities and reagent replenishment policies for the reagent at each man-
ufacturing facility and (ii) specimen and reagent transshipment and bioreactor relocation
policies. The solution of the proposed models gain insights for capacity planners on
• How many bioreactors should be invested at each facility?
• How many units of reagent should each facility order?
• When and where to transship specimen or reagent and relocate bioreactors to ensure
a desired level of resilience with lower cost?
4.1.1 Literature review
The problem considered in this chapter involves capacity planning, resource sharing and
management under supplier disruption risks. Resource sharing operations considered in
this chapter includes demand sharing (transshipping specimens), inventory transshipping
(transshipping reagent) and equipment relocation (relocating bioreactors). Related liter-
ature on capacity planning is presented in Chapter 2. Therefore, we focus on reviewing
multi-location resource sharing and mitigating supplier disruption risks in a decentralized
network.
Resource sharing. Multi-period inventory replenishing and transshipping in a supply
chain network is proposed in [63] and [64]. [65] demonstrates the potentials of trans-
shipping strategies outperforming a centralized system using a two facility example. [66]
and [67] investigate how inventory transshipping is able to increase supply chain leagility
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corresponding to the number of fulfillment nodes in a supply chain. [68] discuss inven-
tory sharing in a two-location network for make-to-stock product. Different structure of
supply chain allowing inventory transshipping is compared in [69]. A two-echelon single-
warehouse multiple-retail supply chain with transshipping is considered in [70] and [71].
Equipment (usable resource) relocation problem is similar to a dynamic facility location
problem. Single facility (batched capacity) relocation problem is studied in [72] and [73],
and multiple facility relocation problem is studied in [74, 75, 76]. A production capacity
relocation problem and inventory control problem is studied in [5], and a storage capacity
relocation problem is studied in [6]. Our research distinguish from existing literature: (i)
We consider demand sharing as our product is build-to-order and personalized, the trans-
shipping of patient specimen is unique; (ii) The total production capacity in our system
is not fixed or predetermined. The availability process of bioreactors is a dynamic pro-
cess, and the total number of production capacity is a decision variable in our problem;
(iii) We consider mitigating supplier disruption risk with resource sharing and extra buffer
inventory.
Mitigating supplier disruption risks in a decentralized network. Modeling supplier
disruptions and inventory control problems under supplier disruption risks in a centralized
network are reviewed in Chapter 3. Due to regulatory requirement multi-sourcing [77, 78]
is an invalid strategy to mitigate supplier disruption risks. [79] shows that a decentralized
network structure, even without transshipping inventory, reduces cost variance through the
risk diversification effect. Given inventory replenishment plans, inventory transshipping in
a two-retailer network with supplier disruptions is studied in [80]. [81] and [82] extend
the two-location problem to n-retailer (n > 2) cases. [83] extends [80] with joint inven-
tory replenishing and transshipping decisions. [84] studies inventory transshipping with
demand distribution updates. Mitigating supplier disruption with demand sharing and pro-




We model capacity planning problems in decentralized networks in Section 4.2. Analysis
of the proposed models are presented in Section 4.3. Solution algorithms are presented
in Section 4.4. In Section 4.5, we compare different decentralized models and different
heuristic polices based in part on data collected from a CAR-T cell therapy manufacturing
facility at the University of Pennsylvania. Testing results suggest that instead of increasing
resource redundancy in all facilities, the Co-Net model only restore limited level of redun-
dancy and adaptively reconfigure the network with lower investment and operational costs.
We conclude this chapter in Section 4.6.
4.2 Problem Formulation
Consider a network of geographically distributed manufacturing facilities, each of which
uses reusable resources (bioreactors) and consumable resources (reagent) during manufac-
turing. There are multiple ways to manage such a network; we consider two. First, we
consider the case where each facility is managed independently of the other facilities, is
focused on serving its regional demand, and hence is essentially isolated from the other
facilities. We refer to this case as the Iso-Net case. Second, we consider the case where
the facilities coordinate and collaborate with each other, when appropriate. We refer to this
case as the Co-Net case.
In an Iso-Net, the decisions we consider include:
(i) The capital investment plan (determining the total amount of bioreactors in the net-
work) and the assignment plan (assigning bioreactors to different facilities)
(ii) For each facility, the consumable replenishment plan (determining the reagent re-
plenishment policy for each facility).
We assume the capital investment and assignment plans are design decisions made initially
that hold over the entire planning horizon and that the consumable replenishment decisions
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are operational decisions made at each decision epoch over the planning horizon. Decisions
that we consider for Co-Net include all the decisions in the Iso-Net and additionally :
(iii) Demand sharing plans (determining policies for transshipping specimens among dif-
ferent regions)
(iv) Manufacturing capacity relocation plans (determining policies for bioreactor reloca-
tion)
(v) Material transshipping plans (determining policies for reagent transshipment),
where the additional plans, all operational, make decisions at each decision epoch.
We assume the network has L facilities, the finite problem horizon contains T decision
epochs, and T epochs are required for therapy manufacturing. We assume that T is consid-
erably smaller than T . For example, assume epochs occur weekly, three weeks are required
to manufacture a therapy (T = 3), and the problem horizon contains 52 epochs (T = 52).
Let [·] be the set operator such that [z] = {1, ..., z} for any integer z ≥ 1. At epoch t let
• st = {slt, l ∈ [L]}, where slt ≥ 0 is the number of specimens waiting for therapy
manufacturing to begin at facility l at epoch t
• bt = {blt, l ∈ [L]}, where blt = (b
l,0




t ≥ 0 is the number of bioreactors
at facility l at epoch t that are τ epochs from completing therapy manufacturing, and
where bl,0t is the number of idle bioreactors at facility l at epoch t
• rt = {rlt, l ∈ [L]}, where rlt ≥ 0 is the number of units of reagent at facility l at
epoch t
• At = {Alt, l ∈ [L]}, where Alt is the maximum number of units of reagent that can be
supplied to facility l at epoch t. The dynamic of the process {At, t ≥ 0} is described
by the epoch and action invariant Markov chain Pr(At+1|At).
We assume there are five sets of action to select at each epoch t ∈ [T ].
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t}] is the number of therapies that are selected to begin
manufacturing at epoch t ∀l ∈ [L]
• wlt ∈ Z = {. . . ,−1, 0, 1, . . . } is the number of specimens transshipped into location l
after mlt is decided and before epoch t+1. A negative valued w
l
t indicates specimens
are transshipped out from facility l. We assume the number of specimens in the





• alt ∈ {0} ∪ [Alt] is the number of units of reagent ordered at epoch t and received
before epoch t+ 1, ∀l ∈ [L]
• elt ∈ Z is the number of units of reagent transshipped after at is received and before
epoch t + 1. We assume the number of units of reagent in the network is identical





• qlt ∈ Z is the number of bioreactors relocated after b
l,1
t bioreactors become to idle and
before epoch t+ 1. We assume the number of bioreactors in the network is identical





Note that we assume transshipped specimens and reagent and relocated bioreactors at epoch
t arrive before epoch t + 1. For example, assume epochs occur weekly and transship-
ping/relocation are a few days. However, if epochs occur daily or twice a day, it require to
model transshipping/relocation lead time. Let dt = (d1t , ..., d
L
t ) be stochastic demands oc-
curred during period t. We assume regional demands are independent, and leave correlated
regional demand as a topic of future research. The system dynamics are
slt+1 = s
l
t −mlt + dlt + wlt, rlt+1 = rlt −mlt + alt, P r(At+1|At),
bl,τt+1 =





t τ = 0,
bl,τ+1t 1 ≤ τ ≤ T − 2,
mlt τ = T − 1.
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The state of the network then becomes xt = (st,bt, rt,At). We use the {At, t ∈ [T ]} pro-
cess to model a variety of ways that supply can be restricted, uncertain, or correlated across
facilities. This model can consider situations that include: (i) the lth supplier can only
allocate up to Alt units of reagent to the firm because of supplier manufacturing capacity
constraints and/or supply commitment to other firms, (ii) the supplier cannot totally predict
how many units of reagent it can provide at the next decision epoch due to an unpredictable
production rate and/or unpredictable orders from other customers with higher priority, (iii)
a quality evaluation failure at the supplier, (iv) correlations across facilities. As an example
of the fourth situation, if two facilities use the same supplier, then a reduction in produc-
tion rate at the supplier will reduce the availability of reagent for both facilities, a positive
correlation. We remark that there is a close relationship between models of relocatable
manufacturing capacity for manufacturing supply chains and models of mobile storage ca-
pacity for urban package express networks [6]. For package express networks, pickup and
delivery rates and hence storage demand for residential areas and business areas are often
negatively correlated.
We assume that transshipment/relocation decisions are made at the beginning of each
decision epoch before the realization of patient demands. Facility l is able to transship at




t −mit) specimens in period t, so that








t = 0, the right-hand side inequality is redundant and thus the
action space of specimen transshipment is





Similarly, the action space of reagent transshipment and bioreactor relocation are,





{qt ∈ ZL : qlt ≥ −(b
l,0







Let the single period cost accrued in period t be additive over facilities
























t|xlt), consist multiple cost compo-
nents
• cRalt is the reagent replenishment cost for the reagent, where cR is the cost per unit
of regent
• hR(rlt+1−slt+1)+ is the reagent overstock holding cost, charged if there are more units
of reagent than specimens at epoch t + 1, where hR is the holding cost per excess
unit of reagent
• hB(bl,0t+1 − slt+1)+ is the bioreactor overstock holding cost, charged if there are more
idle bioreactors than specimens at epoch t + 1, where hB is the bioreactor holding
cost per excess idle bioreactor
• pR(slt+1 − rlt+1)+ is the reagent understock penalty, charged if there are less units of
reagent than specimens at epoch t + 1, where pR is the penalty cost per insufficient
unit of reagent
• pB(slt+1 − b
l,0
t+1)
+ is the bioreactor understock penalty, charged if there are less idle

















































Then, a capacity planning operation phase problem of Co-Net can be modeled as a dynamic
programming problem
v∗t (xt) = min
wt,at,et,qt,mt
E[C(wt, at, et,qt,mt,dt|xt) + βv∗t+1(xt+1)] (Co-Net-o)








qlt = 0, (4.1b)
wlt ≥ −(slt −mlt) ∀l, (4.1c)
elt ≥ −(rlt −mlt + alt) ∀l, (4.1d)
qlt ≥ −(b
l,0
t −mlt + b
l,1
t ) ∀l, (4.1e)





where β is a discount factor and boundary condition vT +1(x) = 0. A capacity planning
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1 , ..., b
L,0
1 )). (Co-Net-d)
We remark that by setting wt = et = qt = 0 for all t in (Co-Net-o), the Co-Net model
becomes an Iso-Net model, with a operation phase problem
v†t (xt) = min
wt,at,et,qt,mt
E[C(wt, at, et,qt,mt,dt|xt) + βv†t+1(xt+1)] (Iso-Net-o)
s.t. 0 ≤ at ≤ At,
wt = et = qt = 0,












1 , ..., b
L,0
1 )). (Iso-Net-d)
Existences of optimal policy for (Co-Net-o) and (Iso-Net-o) are guaranteed by results in











t}, we can always
find a larger feasible mlt that gives no higher single period cost; (ii) inductively the same
fact hold for multi-period cost-to-go functions. Therefore, we reduce the action space by
transforming decision variables mlt to deterministic variables. This suggest that in a Co-
Net, each facility should process at most of its own pending productions and only consider










the remainder of this chapter.
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4.3 Analysis
We first present bound results on an optimal expected total cost of a Co-Net. Let (b1,0∗1 , ..., b
L,0∗
1 )
be an optimal design of a Co-Net and an optimal expected total cost is
u∗(b1,0∗1 , ..., b
L,0∗







1 , ..., b
L,0∗
1 )).
Let (b1,0†1 , ..., b
L,0†
1 ) be an optimal design of an Iso-Net with the same cost parameters; and
an optimal expected total cost is
u†(b1,0†1 , ..., b
L,0†







1 , ..., b
L,0†
1 )).
Since a Co-Net model is a relaxation of an Iso-Net model, the Iso-Net optimal cost upper
bounds the optimal cost of the Co-Net model, i.e. u∗(b1,0∗1 , ..., b
L,0∗
1 ) ≤ u†(b
1,0†
1 , ..., b
L,0†
1 ).
We then present a lower bound construction on the expected total cost of a Co-Net.
The construction include two parts (i) set resource sharing costs are zero, KS = KR =
KB = 0 and (ii) assume specimens, bioreactors (at any production stage) and reagent can
be immediately shared before therapy production mt for all t. The constructed model is a



























t for all t and τ , and a revised system state
xt = (st, bt, rt,At), where bt = {bτt }. Construct a single period cost





t − st − dt)+ + pB(st + dt − b0t − b1t )+,
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then a constructed single facility model has an operation phase problem
v]t(xt) = min
at,mt∈Z
E[C](at, dt|xt) + βv]t+1(xt+1)] (L1-Apx-o)





















We name the constructed problem Single Location Approximation (L1-Apx) problem. Let
b0]1 be an optimal solution of (L1-Apx-d) and an optimal expected total cost is







The following theorem present upper and lower bounds of Co-Net total cost.
Theorem 4.3.1. Given the same cost parameters, then
u](b0]1 ) ≤ u∗(b
1,0∗
1 , ..., b
L,0∗
1 ) ≤ u†(b
1,0†
1 , ..., b
L,0†
1 ).
Proof of Theorem 4.3.1 is presented in Appendix A. The lower and upper bounds can
be solved by solving L = 1 model(s): (i) L1-Apx is a single facility model with modified
transition dynamic of {At} and (ii) Iso-Net is separable by facility, which can be decom-
posed into L single facility models. We note that an L = 1 model is discussed extensively
in Chapter 3 as an FBQ-sdr model.
Next we present a key result which advise the algorithm design of search algorithm to
determine an optimal Co-Net system design (total number of bioreactors at each location).
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We show the convexity of an expected total cost given system design b1,01 , ..., b
L,0
1 .
Theorem 4.3.2. u∗(b1,01 , ..., b
L,0








1 , ..., b
L,0
1 )) is convex in design
variables, i.e. b1,01 , ..., b
L,0
1 .
The above theorem implies an efficient search algorithm, e.g. coordinate decent search,
to find a global minimum of (Co-Net-d) (see [85]). Proof of Theorem 4.3.2 is included in
Appendix A. The following result is straightforward.
Corollary 4.3.3. u†(b1,01 , ..., b
L,0








1 , ..., b
L,0
1 )) is convex in design




Solving an Iso-Net model is equivalent to solve L FBQ-sdr models (with n = 1) proposed
in Chapter 3. Therefore, we focus on solution algorithms for Co-Net models, i.e. (Co-Net-
d) and (Co-Net-o).
4.4.1 Solving Co-Net-d
Suppose we are able to evaluate an expected total operation cost v∗1 for any system design,
i.e. b1,01 , ..., b
L,0
1 . Theorem 4.3.2 suggests that a global minimum can be iteratively searched
using a coordinate descent algorithm. The optimality and convergence of the proposed
coordinate descent algorithm is guaranteed by Theorem 4.3.2.
In iteration k, the coordinate descent algorithm sample an improving coordinate, choose
a searching step size δk, and evaluate
v∗1(x1(b
1,0
1 , ..., b
ik,0
1 − δk, ..., b
L,0




1 , ..., b
ik,0
1 + δk, ..., b
L,0
1 )).
We remark that the learning step size δk is a non-increasing integer such that limk→∞ δk =
1. Update bik,01 to the design candidate from {b
ik,0




t + δk} that produces the
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smallest total cost u∗. Keep iterating until a stopping criterion, e.g. maximum iteration
or cost improvement threshold, is satisfied. Details of the coordinate descent search is
summarized in Algorithm 2.
Algorithm 2: Coordinate descent search for (Co-Net-d)
1 Initialization: choose an initial bioreactor investment and assignment plan
(bl,01 , ..., b
L,0
1 ); choose an initial searching step size δ1; choose maximum iteration
K, set k ← 1;
2 Evaluate v∗1(x1(b
1,0
1 , ..., b
L,0
1 )), and calculate u
∗(b1,01 , ..., b
L,0
1 );
3 while k ≤ K do
4 Sample an improving coordinate ik ∈ [L];
5 Evaluate v∗1(xt(b
1,0
1 , ..., b
ik,0





1 , ..., b
ik,0
1 + δk, ..., b
L,0
1 ));
6 Calculate u∗(b1,01 , ..., b
ik,0
1 − δk, ..., b
L,0
1 ) and u
∗(b1,01 , ..., b
ik,0
1 + δk, ..., b
L,0
1 );
7 if u∗(b1,01 , ..., b
ik,0
1 − δk, ..., b
L,0
1 ) < u
∗(b1,01 , ..., b
ik,0
1 , ..., b
L,0
1 ) then
8 bik,0t ← b
ik,0
t − δk;
9 else if u∗(b1,01 , ..., b
ik,0
1 + δk, ..., b
L,0
1 ) < u
∗(b1,01 , ..., b
ik,0
1 , ..., b
L,0
1 ) then




12 Set k ← k + 1 and update searching step size δk;
13 end
14 Output: Bioreactor investment and assignment plan (bl,01 , ..., b
L,0
1 ) and expected




Solving a Co-Net problem is more complex than the L1-Apx and Iso-Net problems due
to state space complexity and the stochasticity of demand process and supplier disruption
process at all locations. Given a bioreactor system design, (b1,01 , ..., b
L,0
1 ), it is often a chal-
lenge to solve an exact dynamic programming problem to obtain v∗1(x1(b
1,0
1 , ..., b
L,0
1 )), i.e.
Co-Net-o. The output of solving a Co-Net-o problem is a policy which is a functional map-
ping a system state to a control action. The computational challenge motivate our research
in design of near-optimal heuristics. We propose three heuristics based on Approximate
Dynamic Programming (ADP) [86, 87, 88, 89], which solves surrogate models with ap-
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proximated cost-to-go functions. Let π = {πt}t∈[T ] be a policy obtained from an ADP
heuristic, and vπ1 (xt(b
1,0
1 , ..., b
L,0
1 )) be an expected total operation phase cost when policy π
is implemented. We then obtain a solution of Co-Net-d by substituting v∗1(xt(b
1,0





1 , ..., b
L,0
1 )) in the coordinate descent search (Algorithm 2). The proposed
heuristic algorithms are named myopic, extended myopic and mean demand lookahead.
Myopic heuristic (MYO)
Let Π(xt) be an action space at epoch t, i.e.










wlt ≥ −(slt −mlt + dlt), elt ≥ −(rlt −mlt + alt), qlt ≥ −(b
l,0
t −mlt + b
l,1
t ),∀l.}
The MYO heuristic minimizes a single period cost at epoch t
min
(wt,at,et,qt)∈Π(xt)
E[C(wt, at, et,qt,mt,dt|xt)] (MYO)
This heuristic is myopic as the cost-to-go function is ignored. (MYO) can be reformulated
as a mix integer programming (MIP) problem.
Extended myopic heuristic (E-MYO)
Due to the fact that a myopic policy would potentially understock reagent if a supplier
disruption occurs, we extend the myopic heuristic by hybridizing
(i) Reagent inventory replenishment decision by solving an computational efficient Iso-
Net model, denoted as ât
(ii) Resource sharing decision by solving a single period cost minimization problem,
given reagent inventory replenishment policy at = ât.
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Let Π(xt|ât) be a hybrid action space at epoch t, i.e.










wlt ≥ −(slt −mlt + dlt), elt ≥ −(rlt −mlt + âlt), qlt ≥ −(b
l,0
t −mlt + b
l,1
t ),∀l.}




E[C(wt, ât, et,qt,mt,dt|xt)]. (E-MYO)
(E-MYO) can also be reformulated as a MIP.
Mean demand lookahead heuristic (MDL)
An MDL heuristic extends a MYO heuristic by approximating the cost-to-go function as
the total cost over a lookahead horizon. We calculate the lookahead period cost based
on deterministic state transitions assuming that the realized demands in each lookahead
period equals to the mean demand. For example, given st, we cast deterministic state
transition st+1 = st −mt + d̄, where d̄ is the mean demands per period. However, we use
distributional demand to calculate the expect cost in each lookahead period.
Let A(L) = {At+1, ...,At+L} be a realization of supplier capacities in an L-period
lookahead horizon, and x̄t+j(A(j)) be a hypothesis state at epoch t + j assuming d̄ and
{At+1, ...,At+j} are realized in the first j lookahead periods. An L-lookahead MDL
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(MDL-L) heuristic solves a multi-period problem
min
(wt,at, et,qt) ∈ Π(xt),
(wt+1(A(1)),at+1(A(1)), et+1(A(1)),qt+1(A(1))) ∈ Π(x̄t+1(A(1))), ...,










(MDL-L) can be reformulated as a MIP, however, if the carnality of A is huge, the number
of decision variables in (MDL-L) grows exponentially. Therefore, we would rely on cut
generation methods (i.e. Benders decomposition) [90, 91, 92] to accelerate the computa-
tional process of proper decisions (wt, at, et,qt).
4.5 Case Studies
4.5.1 Case study 1: the potential of resource sharing
We investigate cost efficiency of a dynamic resilient network, i.e. a Co-Net, comparing
to a traditional node resilient network, i.e. an Iso-Net, under the same resiliency attitude,
i.e. identical pB and pR in the Co-Net and Iso-Net problems. We consider a two facil-
ity network (L = 2), and the specifications of the facilities are based on the Clinical Cell
and Vaccine Production Facility (CVPF) at the University of Pennsylvania (see Table 4.1).
We adopt system specification (e.g. demand distribution, production duration, etc.) from
[7], and adopt cost assessments from [14]. Resource sharing costs are estimated based on
consultations with researchers at the NSF Engineering Research Center for Cell Manufac-
turing Technology (CMaT). We consider a simply supplier disruption profile described by
two independent Bernoulli processes, Ber(p1) and Ber(p2): at each decision epoch, the
supplier of facility 1 has a probability of p1 to be disrupted and be not able to supply any
reagent; and the supplier of facility 1 has a probability 1− p1 to be undisrupted and be ca-
pable to supply as much reagent as required; and similar for the supplier disruption process
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Table 4.1: System specs and cost parameters – Chapter 4 case study
Parameter Type Value
Fd distribution Poisson(4.81)
T scalar 3 weeks










Ber(p2). Using Iso-Net as a baseline model, we compare performances of four heuristics:
MYO, E-MYO, MDL-1 and MDL-2. MDL-1 is an MDL heuristic with one lookahead
periods, and MDL-2 is an MDL heuristic with two lookahead periods. We consider four
supplier disruption profiles, let p = [p1, p2]:
(i) Mild: p1 = p2 = 0.1
(ii) Moderate: p1 = p2 = 0.3
(iii) Severe: p1 = p2 = 0.6
(iv) Asymmetric: p1 = 0.3 and p2 = 0.6.
Testing results in this section are based on 400 simulation scenarios. Several perfor-
mance measures reported include: average expected total cost, number of bioreactors, av-
erage specimen transshipment, average bioreactor relocation and average reagent transship-
ment. Figure 4.1 depicts the average expected total costs of the baseline Iso-Net and Co-Net
heuristics under each supplier disruption profiles. The MYO heuristic has degraded perfor-
mance comparing to the Iso-Net baseline. MYO heuristic fails to build sufficient reagent
safety stock and hence results in a higher total cost. The E-MYO heuristic utilizes reagent
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Figure 4.1: Case study 1: average expected total cost comparison
decision provided by the Iso-Net baseline to build safety stock which results in significant
cost reductions comparing to MYO. On the other hand, the flexibility of resource sharing
also results in significant cost reduction comparing to the Iso-Net baseline. In the cases of
mild and moderate supplier disruption risk, MDL-1 produces the lowest cost; and in the
cases of severe and asymmetric supplier disruption risk, MDL-2 outperforms the rest of the
methods. This is because of the fact that an MDL heuristic is able to (i) build up sufficient
safety stock, and (ii) utilize the flexibility of resource sharing during the lookahead periods.
Figure 4.2 compares bioreactor quantities suggested by different methods. All Co-Net
heuristics suggest less total bioreactors, see Figure 4.2a. While producing much lower
expected total cost, E-MYO, MDL-1 and MDL-2 reports 9.5% less bioreactor investment
when supplier disruption risk is mild, and E-MYO reports 25% less bioreactor investment
when supplier disruption risk is severe. Allowing bioreactor relocation results in better
bioreactor utilization. In the first three cases, where supplier disruption profiles are sym-
metric, all methods suggest larger bioreactor quantity as the suppliers suffer worse disrup-
tion risks. When the supplier disruption profile is asymmetric, the Co-Net methods intend
to keep buffer bioreactors at the location with more severe supplier risk while keep the
other facility lean, see red dotted lines in Figures 4.2b and 4.2c.
Next, we present the comparison results on resource sharing. Figure 4.3 presents the
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(a) Sum of two facilites











































Figure 4.2: Case study 1: bioreactor quantity comparison
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comparison of average specimen transshipment quantity when different methods are ap-
plied. We not that E-MYO suggests negligible specimen transshipment quantity, since E-
MYO keeps higher redundant reagent stock at both facilities and transshipping reagent is
much cheaper than transshipping patient specimen in our problem setting. This can be ver-
ified by the fact that E-MYO transships more reagent than other methods (see Figure 4.5).
MYO transships the largest number of reagent among all investigated methods. Figure



















Figure 4.3: Case study 1: average specimen transshipment quantity comparison





















Figure 4.4: Case study 1: average bioreactor relocation quantity comparison
4.4 presents the comparison of average bioreactor transshipment quantities when different
methods are applied. We observe the largest bioreactor transshipment quantities for MYO
among all methods. The comparison of average reagent transshipment is presented in Fig-
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ure 4.5. The E-MYO method has the largest reagent transshipment quantities in all testing
scenarios.






















Figure 4.5: Case study 1: average reagent transshipment quantity comparison
4.5.2 Case study 2: the supplier correlations
We investigate how a decentralized network could benefit from a dynamic resilient design
(i.e. Co-Net) if the suppliers of facilities are independent, positively correlated or nega-
tively correlated. We compare performances of four heuristics, MYO, E-MYO, MDL-1
and MDL-2, and use Iso-Net as a baseline model. We consider three supplier correlation
scenarios:
(i) Independent: p1 = p2 = 0.3, and for all t, Pr(A1t = 0|A2t ) = 0.3 for any A2t , and
Pr(A2t = 0|A1t ) = 0.3 for any A1t
(ii) Positively correlated (identical): p1 = 0.3, and for all t, Pr(A2t = 0|A1t = 0) = 1
and Pr(A2t =∞|A1t =∞) = 1
(iii) Negatively correlated (flipped): p1 = 0.3, and for all t, Pr(A2t = ∞|A1t = 0) = 1
and Pr(A2t = 0|A1t =∞) = 1.
We note that the Iso-Net baseline solves two centralized network models for scenario (i)
and (ii) with p1 = p2 = 0.3, and solves two centralized network models for scenario (iii)
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with p1 = 0.3 and p2 = 0.7. Testing results in this section are based on 400 simulation
scenarios. We compare performances of different methods based on average expected total
cost, number of bioreactors, average specimen transshipment, average bioreactor relocation
and average reagent transshipment.
Figure 4.6 depicts average expected total cost of the baseline Iso-Net and Co-Net heuris-
tics in each supplier correlation scenario When the suppliers are independent, the MYO
























Figure 4.6: Case study 2: average expected total cost comparison
heuristic has degraded performance comparing to the baseline Iso-Net, while the other three
Co-Net heuristic outperform the baseline with cost reduction as large as 14.3% (MDL-1).
In the case of identical (strong positively correlated) suppliers case, MYO and MDL-1
both failed to reduce the total cost comparing to the baseline Iso-Net. E-MYO and MDL-2
have negligible cost reduction comparing to the baseline. When suppliers are strong neg-
atively correlated, flipped supplier states in our case, resource sharing produce the largest
cost reduction. All Co-Net methods outperform the baseline Iso-Net with the largest cost
reduction of 38.2% (MDL-1).
Figure 4.7 compares bioreactor quantities in different supplier correlation scenarios.
The largest bioreactor investment saving occurs when the suppliers are negatively corre-
lated, i.e. the E-MYO achieves 33.3% less bioreactors comparing to the baseline Iso-Net
while reducing the expected total cost at the same time. We observe less resource sharing
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Figure 4.7: Case study 2: bioreactor quantity comparison
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when the suppliers are positively correlated, and more resource sharing when suppliers are
negatively correlated (see Figures 4.8-4.10 for comparison of average specimen transship-
ping, bioreactor relocation and reagent transshipping quantities).






















Figure 4.8: Case study 2: average specimen transshipment quantity comparison





















Figure 4.9: Case study 2: average bioreactor relocation quantity comparison
4.6 Conclusions
We have modeled and analyzed the capacity planning problem in a decentralized network
under supplier disruption risk to determine the best number of bioreactors in each facility,
the best reagent replenishment policy, and the best resource sharing plans. For the case
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Figure 4.10: Case study 2: average reagent transshipment quantity comparison
where facilities are operated isolatedly (Iso-Net), we show it is equivalent to solve multiple
centralized regional networks. For the case where facilities are coordinating by resources
sharing (Co-Net), we analyze structural properties of Co-Net, discuss computational chal-
lenges and develop heuristic algorithm to solve the Co-Net models. In the case studies, we
compare different decentralized models and different heuristic polices based in part on data
collected from a CAR-T cell therapy manufacturing facility at the University of Pennsylva-
nia. Testing results suggest that instead of increasing resource redundancy in all facilities,
the Co-Net model only restore limited level of redundancy and adaptively reconfigure the
network with lower investment and operational costs.
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CHAPTER 5
CONCLUSION AND FUTURE RESEARCH
In this Ph.D. thesis, we investigate a class of problems called resilient capacity planning
in reconfigurable supply chains for build-to-order manufacturing system and service-upon-
request service system. Several key fundamental research projects are investigated on de-
cision supports to achieve dynamic resiliency in reconfigurable supply chains.
We introduce key concepts, such as capacity planning, reusable resource, consumable
resource, relocatable manufacturing/service module, centralized/decentralized network, re-
configurability, supplier disruption and dynamic resilience. Using personalized medicine
as motivating example, our research address modeling, analysis and algorithm design in
both centralized and decentralized network with and without supplier disruption risks. In
Chapter 2, we investigate approaches for determining the number of reusable resources
and a replenishment policy for consumable resources in a centralized network, e.g. an
autologous build-to-order cell therapy manufacturing system. We consider two capacity
planning models, one where the number of bioreactors is adjustable at each decision epoch
and one where this number can only be adjusted periodically. For each model, we examine
two variants, one where there are penalties for an insufficient number of bioreactors and
units of reagents and one where there are chance constraints on an insufficient number of
bioreactors and units of reagents. In a case study, we determine an optimal or near-optimal
number of bioreactors and a reagent replenishment policy based in part on data collected
from a CAR-T cell therapy manufacturing facility at the University of Pennsylvania. In
Chapter 3, We investigate approaches to determine the number of reusable resources and a
replenishment policy for consumable resources in a centralized network, e.g. an autologous
build-to-order cell therapy manufacturing system, in the face of supplier disruption risks.
We model a supplier disruption process as an exogenous Markov process. Incidents that
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cause reagent shortages include natural disasters, human errors and disease outbreaks. We
consider two capacity planning models, one where the number of bioreactors is adjustable
at each decision epoch and one where this number can only be adjusted periodically. Both
models are formulated as Markov decision processes (MDP). We propose algorithms to
solve the proposed models. In the case studies, given different supplier disruption sce-
narios, we determine bioreactors adjustment quantities and reagent replenishment policies
based in part on data collected from a CAR-T cell therapy manufacturing facility at the
University of Pennsylvania. In Chapter 4, we investigate a capacity planning problem to
determine the number of reusable resources, a replenishment for consumable resources
and resource sharing plans in a decentralized network under supplier disruption risks. We
consider two kinds of decentralized networks. The first network has isolated regional fa-
cilities (Iso-Net), while the second network has coordinated regional facilities (Co-Net).
In an Iso-Net, each facility fulfills its regional demand with its own capacity; while in a
Co-Net, all facilities coordinate by sharing demand and transshipping resources (bioreac-
tor and reagent). The second supply chain is reconfigurable as production capacities in
different facilities are dynamically adjustable. We show that a coordinating and recon-
figurable decentralized network exhibit greater resilience with lower costs in the face of
supplier disruption risks. We introduce computational challenges of solving Iso-Net and
Co-Net models, which motivate our research in design of efficient and effective heuristic
algorithms. In the case studies, we construct a hypothetical decentralized network based in
part on data collected from a CAR-T cell therapy manufacturing facility at the University
of Pennsylvania. We compare decentralized models and different heuristic polices based
on the constructed decentralized network. Testing results suggest that instead of increasing
resource redundancy in all facilities, it is beneficial to only restore limited level of redun-
dancy and adaptively reconfigure the network.
We finalize this thesis by discussing open questions and proposing future research top-
ics.
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(I) Perishability: Perishable consumable resource with fixed lifetimes has to be used
before their expiration date or otherwise will become outdated and removed from
inventory. Waste and financial loss due to outdating can be significant. For example,
approximately 10% of the total inventory of certain important blood products out-
dated in 2017 (see [93]) and approximately 17% of unsellable products in the health
and beauty, food, and beverage industries is due to outdating (see [94]). These facts
support the claim that inventory control for products that outdate is an important
topic for analysis, particularly when the consumable represents a significant portion
of the cost of goods. An extension of works in this thesis is to consider reagent as a
perishable inventory.
(II) Patient withdrawal: Patients waiting for cell therapy transplant may withdraw their
requests if the patient is not eligible for the treatment due to degradation of the pa-
tients’ health states or patient mortalities (see [7]). Understanding and modeling a
withdraw process of the specimen queue is a valuable extension. Penalty costs would
be redesigned to relate patient withdrawal to some direct and undirect cost measures.
(III) Intentional supplier disruption: Instead of modeling a supplier disruption process
as a exogenous stochastic process, some supplier disruptions may be intentional.
An adversary could disrupt a set of suppliers in the network. Then at each deci-
sion epoch, we can model a two agent game: a capacity planer chooses a reagent
replenishment and a resource sharing plan, and an adversary chooses an attacking
plan. Then the multi-period capacity planning problem can be extended to a dynamic
game.
(IV) Demand variation and correlation: Instead of stationary demand, total/regional
demand may surge or reduce significantly. In addition, regional demands may be
correlated. Modeling demand variation and correlation and capacity planning with
nonstationary and correlated demand bring additional challenges in resilient capacity
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planning.
(V) Real-world decentralized network case study: A more complex real-world decen-
tralized network data can be collected from industrial collaborators. Applying the
resilient capacity methods to real-world case studies will generate more insights of





A.1 Chapter 2 Proofs
A.1.1 Proof of Proposition 2.2.1
Rewrite the single period cost
C(qt, at,mt, dt|xt) =cBqt + cRat + hB(qt + b0t + b1t − st − dt)+ + hR(rt + at − st − dt)+
+ pB(st + dt − qt − b0t − b1t )+ + pR(st + dt − at − rt)+,
whose value does not depend on mt. Since only the difference of st+1 and b0t+1 and the
difference of st+1 and rt+1 affected the costs for all t, we can easily verify that the total
cost does not depend on the choice of mt. Thus, mp(xt) is optimal. Let yt = rt + at and













E{G(zt, yt, dt|xt) + βv∗(xt+1)}. (A.2)
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where
G(zt, yt, dt|xt) = (hR + (1− β)cR)(yt − (st + dt))+ + (pR − (1− β)cR)(st + dt − yt)+
+ (hB + (1− β)cB)(zt − (st + dt))+ + (pB − (1− β)cB)(st + dt − zt)+.
Lemma A.1.1. Assume E{dt} <∞ and mt is uniformly bounded for all t. Then, a policy
optimal for (A.1) is optimal for (A.2), and conversely.
Proof. (Lemma A.1.1) We construct a function as the following





cBmt+n−(T−1) + (cR + cB)E{dt}
}
,
and in addition, we can examine thatG(zt, yt, dt|xt) = C ′(zt, yt, dt|xt)+βφ(xt+1)−φ(xt).
Suppose there exists and optimal policy δ, that maps the state space to the action space at
each epoch t, i.e. δ(xt) = (zδt , y
δ
t ), then
v(xt) = E{C ′(zδt , yδt , dt|xt) + βv(xt+1)} = E{G(zδt , yδt , dt|xt)− βφ(xt+1) + φ(xt) + βv(xt+1)},
and hence let v̄(xt) = v(xt) − φ(xt), we have v̄(xt) = E{G(zδt , yδt , dt|xt) + βv̄(xt+1)},
which satisfied the optimality equation for (A.1). To show the converse direction result,
simply construct φ̄(xt) = −φ(xt) and simply apply the same proof with the roles of (A.1)
and (A.2) interchanged. 
We remark that mt is uniformly bounded if the number of bioreactors is finite. We
note that E{G(zt, yt, dt|xt)} is convex in zt and yt. Let z∗(xt) and y∗(xt) be the smallest













. We remark that mt ≤ st
implies mt ≤ zpt (xt). Thus, in the single stage problem a myopic policy has a base stock
policy structure: qp(xt) = zp(xt) − (b0t + b1t ) and ap(xt) = (yp(xt) − rt)+. Therefore, it’s
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straight forward to verify that mt ≤ zp(xt) and rt ≤ yp(xt), and
mt+1 = min{st+1, b0t+1, rt+1} ≤ st+1 ≤ st+1 + F−1d
(






p(xt)−mt = st + F−1d
(




≤ st + F−1d
(
pR − (1− β)cR
pR + hR
)
−mt + dt = yp(xt+1).
Therefore if (A1) holds, (A.2) can be decomposed into a series of single period newsvendor
problem, where each newsvendor problem is solved by the myopic base stock policy.
A.1.2 Proof of Corollary 2.2.2
Let (q∗, a∗,m∗) and (q†, a†,m†) be optimal policies of ABQ-p and (2.2), respectively.
m∗ = m† = mp holds trivially. Let yt = rt + at and zt = qt + b0t + b
1
t , then
Ĉ(qt, at,mt, dt|xt) =cBqt + cRat + hB(zt − st − dt)+ + hR(yt − st − dt)+
+ p(st + dt −min{zt, yt})+
and
C(qt, at,mt, dt|xt) =cBqt + cRat + hB(zt − st − dt)+ + hR(yt − st − dt)+













Therefore q∗t = z
∗
t−(b0t+b1t ) = qp and a∗t = y∗t−rt = ap. On the other hand, if pB+pR = p,
it is easy to see that Ĉ(qt, at,mt, dt|xt) ≥ C(qt, at,mt, dt|xt). By definition of q∗ and a∗,










and a†t = a∗t achieve minimized long-term total cost by a similar construction and induction
in the proof in Section A.1.1.
A.1.3 Proof of Proposition 2.2.3
The single period costs in C̃(qt, at, dt|xt) are monotonically non-decreasing in at and qt
for all t. The chance constraints are equivalent to Pr[st + dt > b0t + b
1
t + qt] ≤ αB and
Pr[st + dt > rt + at] ≤ αR. Pr[st + dt > b0t + b1t + qt] and Pr[st + dt > rt + at] are
monotonically non-increasing in qt and at, respectively. Thus, the solution of ABQ-c is to
minimize at and qt, subject to at ≥ 0, qt ≥ −(b0t −mt + b1t ), and the chance constraints.
Then at and qt must satisfy
rt + at ≥ F−1d (1− αR) + st, at ≥ 0,
b0t + b
1
t + qt ≥ F−1d (1− αB) + st, qt ≥ −(b
0
t −mt + b1t ).
Therefore, a∗(xt) = (st +F−1d (1−αR)− rt)+ and q∗(xt) = st +F
−1
d (1−αB)− (b0t + b1t ).
The optimality of m∗(xt) is similar with the argument on mp(xt) in Section A.1.1.
A.1.4 Proof of Proposition 2.3.2
Let u(x1|q1, a) = E{C̃(q1, a(x1), d1|xt)+βv2(x2|q1, a(x1))}. Suppose there exists another
feasible policy (q′1, a
′) such that u(x1|q′1, a′) < u0(x0|q∗, a∗). By Proposition 2.3.1 and the
definition of q∗,
u(x1|q∗1, a∗) > u(x1|q′1, a′) ≥ u(x1|q′1, a∗) ≥ u(x1|q∗1, a∗),
which is a contradiction.
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A.1.5 Proof of Proposition 2.3.3
(i) Let d = {d1, ..., dT } be a realization of demand over the planning horizon, and d(t)
be the first t elements of d, i.e. d(t) = {d1, ..., dt}.
Lemma A.1.2. Pr[st+1 > b0t+1|x1,d(t), q1] is non-increasing in q1.
Proof. (Lemma A.1.2) Given x1, d(t) and a∗, st+1 and b0t+1 can be explicit as:





1 −m1 + b11 − · · · −mt + bt1 t ≤ T − 1
q1 + b
0
1 −m1 + b11 − · · · −mT−1 + bT−11
−mT +m1 − · · · −mt +mt−T+1 t ≥ T,










1 t ≤ T − 1
q1 +B1 +
∑t−T+1
j=1 mj t ≥ T.
(A.3)
It requires to show that the right-hand side of (A.3) is non-decreasing in q1.




1 is non-decreasing in q1;
















is non-decreasing in q1;
Case 3: t ≥ 2T , we show
∑t−T+1














wherem1 is non-decreasing (shown in Case 2). Therefore,
∑T+1
j=1 mj is non-decreasing
in q1. Suppose for a t > 2T ,
∑t′−T+1
j=1 mj is non-decreasing in q1 for all t
′ ≤ t, re-
mains to show
∑t+1−T+1


















i=1 mi is non-decreasing in q1 by hypothesis, thus
∑t+1−T+1
j=1 mj is non-
decreasing in q1. 






(ii) By definition of C̃,
C̃(q1, a
∗(x1), d1|x1) = CBq1 + CRa∗(x1) + hB(b12 − s2)+ + hR(r2 − s2)+
= CBq1 + CR(s1 + ZR − r1) + hB(b02 − s2)+ + hR(ZR − d1);
C̃(0, a∗(xt), dt|xt) = CRa∗(xt) + hB(b0t+1 − st+1)+ + hR(rt+1 − st+1)+
= CR(st + ZR − rt) + hB(b0t+1 − st+1)+ + hR(ZR − dt),
where CBq1 is trivially non-decreasing in q1, and CR(s1 + ZR − r1), hR(ZR − d1),
CR(st +ZR− rt) and hR(ZR− dt) are independent with q1. Thus it remains to show
that hB(b0t+1 − st+1)+ is non-decreasing in q1. With a similar derivation as in the
proof of Lemma A.1.2,






1 − (s0 +
∑t
i=1 di) t ≤ T − 1
q1 +B1 +
∑t−T+1
j=1 mj − (s1 +
∑t
i=1 di) t ≥ T,
we can show b0t+1 − st+1 is non-decreasing in q1, which completes our proof.
104
A.1.6 Proof of Proposition 2.3.4
We first show that the lower bound qL(x1, αB) ensures Pr[st+1 > b0t+1|x1, qL(x1, αB)] ≤
αB for t = 1, ..., T , by showing that for k = 1, ..., T , q
(k)
0 is the smallest bioreactor adjust-
ment such that Pr[sk+1 > b0k+1|x1, q
(k)
1 ] ≤ αB is ensured.



















Case 2: For k = T , sT+1 > b0T+1 with a given x1 implies s1 +
∑T









1 ] ≤ αB, we have q1 ≥ s1 + F−1(T )(1−
αB) −m1 − B1 = q(T )1 . To ensure feasibility of the first T bioreactor outage chance con-
straint, q1 need to be no less than the maximum of q
(k)
1 (x1, αB) for k = 1, ..., T . Since
T ≤ T , we claim qL(x1, αB) is a lower bound on an optimal q1.
A.2 Chapter 3 Proofs
A.2.1 Proof of Lemma 3.2.1
Proof. Let w0 = 0 and wn+1 = H̄wn for all n, and gn(zt, yt|xt) = E{G(zt, yt, dt|xt) +
βwn(xt+1)}. For n = 0, g0(zt, yt|xt) = E{G(zt, yt, dt|xt)} is convex in zt and yt. Suppose




∗(xt), rt|xt), rt ≥ y∗(xt)
gn(z
∗(xt), y
∗(xt)|xt), y∗(xt)− At ≤ rt ≤ y∗(xt)
gn(z
∗(xt), rt + At|xt), rt ≤ y∗(xt)− At.
which is convex in rt and irrelevant with bt. Since rt+1 can be expressed as a linear ex-
pression of yt, wn+1 is convex in yt. Therefore gn+1 is convex in zt and yt. Inductively, we
show the convexity of g.
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A.2.2 Proof of Proposition 3.2.5
Proof. It is sufficient to show that the objective functions of the two parts are not dependent
with production quantitym. The reagent inventory level yt+k−st+k−dt+k can be rewritten
as
rt + at + · · ·+ at+k − st − dt − · · · − dt+k
which is independent of mt, ...,mt+k. A similar result can be shown for idle bioreactor
inventory level.
A.2.3 Proof of Lemma 3.2.6
Proof. It is sufficient to show that rt ≤ ȳ(st) ≤ rt + At implies rt+1 ≤ ȳ(st+1) ≤ rt+1 +
At+1. Note rt ≤ ȳ(st) ≤ rt + At is equivalent to
0 ≤ F−1(ρ̄R) + st − rt ≤ At
and rt+1 = F−1(ρ̄R) + st−mt. Therefore, substituting rt+1, rt+1 ≤ ȳ(st+1) ≤ rt+1 +At+1
is equivalent to 0 ≤ dt ≤ At+1, which follows by the assumptions Pr(dt ≤ At) = 1 for all
t and {dt, t ≥ 0} is IID.
A.2.4 Proof of Proposition 3.2.9
Proof. (i) Left ≤: Define gn(zt, yt|xt) = E{G(zt, yt, dt|xt) + βwn(xt+1)}, and let y∗n(xt)
be a minimizer of gn. For n = 0, ȳ(st) = y∗0(xt). Suppose ȳ(st) ≤ y∗n(xt), it is sufficient





= 0, and it is





≤ 0. Let r̄t+1 (s̄t+1) be the inventory level
(specimen queue length) if ȳ is implemented at epoch t, then













(ii) Right≤: By contradiction, suppose y∗(xt) > ŷ(st) for any supplier disruption process,
i.e. {Aτ}τ≥t+1. We can easily construct a counter example, e.g. a disruption process









βk[−pR + (pR + hR)F(k+1)(ȳ(st)− st) ≤ 0,
so that ȳ(st) ≤ ŷ(st). Thus we derive a contradiction,
ȳ(st) ≤ ŷ(st) < y∗(xt) = ȳ(st).
A.3 Chapter 4 Proofs
A.3.1 Proof of Theorem 4.3.1
Proof. The upper bound is obvious: since a Co-Net model is a relazation of an Iso-Net
model, the Iso-Net optimal cost is an upper bound of the Co-Net cost, i.e. u∗(b1,0∗1 , ..., b
L,0∗
1 ) ≤
u†(b1,0†1 , ..., b
L,0†
1 ). We then focus on the lower bound.
Consider the following relaxation of a C-Net model:
(i) Let KS = KR = KB = 0, so that


























t|xlt) =cRalt + hR(rlt+1 − slt+1)+ + pR(slt+1 − rlt+1)+
+ hB(b
l,0










































































































=cRat + hR(rt+1 − st+1) + (hR + pR)(st+1 − rt+1)+ + hB(b0t+1 − st+1)
+ (hB + pB)(st+1 − b0t+1)+
=cRat + hR(rt+1 − st+1)+ + pR(st+1 − rt+1)+ + hB(b0t+1 − st+1)+
+ pB(st+1 − b0t+1)+
=cRat + hR(rt −mt + at +
∑




+ pR(st −mt + dt +
∑






t −mt + b1t +
∑
l




+ pB(st −mt + dt +
∑










t − st − dt)+ + pB(st + dt − b0t − b1t )+ = C̈(at, dt|xt)















t ≤ min{st, b0t , rt}.
Matching the term, we can verify that the relaxed model is essentially (L1-Apx-o) model,
which will provide a lower bound expected total cost.





1 is linear in b
l,0
1 ’s, therefore, it remains to show that v
∗
1 is convex in
bl,01 ’s. Let
gt(wt, at, et,qt,mt|xt) = E[C(wt, at, et,qt,mt,dt|xt) + βv∗t+1(xt+1)],
if we can show that gt is convex in wt, at, et,qt and b
l,0
t ’s, then we can show v∗t is convex
in bl,0t ’s (so that v∗1 is convex in b
l,0
1 ’s) by the following lemma in [95].
Lemma A.3.1. If f(x, y) : Rn × Rm → R is convex in x and y, and Y ∈ Rm is a convex
set, then g(x) = miny∈Y f(x, y) is convex in x.
Therefore, it remains to show that gt is convex in wt, at, et,qt and b
l,0
t ’s. Prove by induc-
tion:
- gT (wT , aT , eT ,qT ,mT |xT ) = E[C(wT , aT , eT ,qT ,mT ,dT |xT )], which is obvi-
ously convex in wT , aT , eT ,qT , sT , rT and b
l,0
T ’s.
- Suppose gt+1 is convex in wt+1, at+1, et+1,qt+1, st+1, rt+1 and b
l,0
t+1’s, then by Lemma
A.3.1, v∗t+1 is convex in st+1, rt+1 and b
l,0
t+1’s. We introduce another lemma from [95].
Lemma A.3.2. If f : Rm is convex, then g(x) = f(Ax + b) is convex in x ∈ Rn for
any A ∈ Rm×n and b ∈ Rm.
Since st+1, rt+1 and b
l,0
t+1’s are linear functions of wt, at, et,qt and b
l,0
t ’s, then by






B.1 Chapter 2 Algorithm Complements
B.1.1 PST Feasibility Checking Algorithm
Algorithm 3: PST feasibility checking
1 Initialization: set N ← inf{N : min{NαB, N(1− αB)} ≥ 5}, choose a
confidence level θ, and calculate testing threshold Ψ−1(θ);
2 Generate N T -period simulation paths with bioreactor adjustment q1 and
base-stock reagent replenishment policy a∗. Collect incidents
δ(i)[st+1 > b
0
t+1|x1, q1], for i ∈ [N ] and ∈ [T ] ;
3 for t ∈ [T ] do









5 if zt > Ψ−1(θ) then
6 Break for loop;
7 end
8 Set k ← t;
9 end
10 Output: ’Feasible’ if k = T , and ’Infeasible’ if k < T .
B.1.2 A Practial Upper bound of q∗1
Consider a finite horizon (ABQ-c) model:
v̄t(xt) = min
qt≥−(b0t−mt+b1t ),at≥0
E{C̃(qt, at, dt|xt) + βv̄t+1(xt+1)} (B.1)
s.t. Pr[st+1 > b
0
t+1|xt] ≤ αB,
P r[st+1 > rt+1|xt] ≤ αR.
and v̄T +1(xT +1) = 0. For a given starting state x1 and threshold αB, for any demand real-
ization scenario d, the idle bioreactor adjustment and reagent replenishment policy yields a
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dynamic total bioreactor quantity dynamics Bt(x1,d(t), αB), where d(t) = {d1, ..., dt−1} is
a truncated demand scenarios that is known at epoch t. LetB(x1,d, αB) = maxtBt(x1,d(t), αB),
which is a random variable. Let FB(x1,αB) be the cdf of B(x1,d, αB), define BU(x1, αB) =
F−1B(x1,αB)(1−αB). Then we obtain an practical upper bound qU(x1, αB) := BU(x1, αB)−
B1. Through our numerical tests on a large amount of input scenarios, qU(x1, αB) is always
a feasible bioreactor adjustment, while proofing this upper bound analytically could be one
of our future research topics.
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